Bausch Health Companies (BHC) 10-Q 4 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	001-14956
Entity Registrant Name	Bausch Health Companies Inc.
Entity Incorporation, State or Country Code	A1
Entity Address, Country	CA
Entity Tax Identification Number	98-0448205
Entity Address, Address Line One	2150 St. Elzéar Blvd. West
Entity Address, City or Town	Laval
Entity Address, State or Province	QC
Entity Address, Postal Zip Code	H7L 4A8
City Area Code	514
Local Phone Number	744-6792
Title of 12(b) Security	Common Shares, No Par Value
Trading Symbol	BHC
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		352,431,217
Entity Central Index Key	0000885590
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 825	$ 721
Restricted cash	2	2
Trade receivables, net	1,747	1,865
Inventories, net	1,100	934
Prepaid expenses and other current assets	631	689
Total current assets	4,305	4,211
Property, plant and equipment, net	1,390	1,353
Intangible assets, net	10,650	12,001
Goodwill	13,052	13,142
Deferred tax assets, net	1,868	1,676
Other non-current assets	402	109
Total assets	31,667	32,492
Current liabilities:
Accounts payable	437	411
Accrued and other current liabilities	3,198	3,197
Current portion of long-term debt and other	100	228
Total current liabilities	3,735	3,836
Acquisition-related contingent consideration	267	298
Non-current portion of long-term debt	23,466	24,077
Deferred tax liabilities, net	879	885
Other non-current liabilities	760	581
Total liabilities	29,107	29,677
Commitments and contingencies (Note 19)
Equity
Common shares, no par value, unlimited shares authorized, 352,387,430 and 349,871,102 issued and outstanding at September 30, 2019 and December 31, 2018, respectively	10,168	10,121
Additional paid-in capital	406	413
Accumulated deficit	(5,936)	(5,664)
Accumulated other comprehensive loss	(2,156)	(2,137)
Total Bausch Health Companies Inc. shareholders’ equity	2,482	2,733
Noncontrolling interest	78	82
Total equity	2,560	2,815
Total liabilities and equity	$ 31,667	$ 32,492

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, no par value (in usd per share)	$ 0	$ 0
Common stock, shares issued (in shares)	352,387,430	349,871,102
Common stock, shares outstanding (in shares)	352,387,430	349,871,102

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues
Revenues	$ 2,209	$ 2,136	$ 6,377	$ 6,259
Expenses
Selling, general and administrative	648	614	1,886	1,847
Research and development	123	107	357	293
Amortization of intangible assets	475	658	1,452	2,142
Goodwill impairments	0	0	0	2,213
Asset impairments	33	89	49	434
Restructuring and integration costs	4	3	28	16
Acquisition-related contingent consideration	3	(19)	2	(23)
Other expense (income), net	10	(15)	15	(3)
Total expenses	1,880	2,019	5,504	8,668
Operating income (loss)	329	117	873	(2,409)
Interest income	2	3	9	9
Interest expense	(406)	(420)	(1,221)	(1,271)
Loss on extinguishment of debt	0	0	(40)	(75)
Foreign exchange and other	9	0	12	18
Loss before benefit from (provision for) income taxes	(66)	(300)	(367)	(3,728)
Benefit from (provision for) income taxes	18	(51)	101	(74)
Net loss	(48)	(351)	(266)	(3,802)
Net (income) loss attributable to noncontrolling interest	(1)	1	(6)	(2)
Net loss attributable to Bausch Health Companies Inc.	$ (49)	$ (350)	$ (272)	$ (3,804)
Basic and diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)	$ (0.14)	$ (1)	$ (0.77)	$ (10.83)
Basic and diluted weighted-average common shares (in shares)	352.4	351.5	351.9	351.1
Product sales
Revenues
Revenues	$ 2,180	$ 2,108	$ 6,291	$ 6,173
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	571	573	1,675	1,717
Other revenues
Revenues
Revenues	29	28	86	86
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 13	$ 9	$ 40	$ 32

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (48)	$ (351)	$ (266)	$ (3,802)
Other comprehensive (loss) income
Foreign currency translation adjustment	(97)	13	(20)	(159)
Pension and postretirement benefit plan adjustments, net of income taxes	0	(1)	(1)	(2)
Other comprehensive (loss) income	(97)	12	(21)	(161)
Comprehensive loss	(145)	(339)	(287)	(3,963)
Comprehensive loss (income) attributable to noncontrolling interest	1	4	(4)	2
Comprehensive loss attributable to Bausch Health Companies Inc.	$ (144)	$ (335)	$ (291)	$ (3,961)

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Shares	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Bausch Health Companies Inc. Shareholders' Equity	Noncontrolling Interest
Beginning Balance (in shares) at Dec. 31, 2017		348,700,000
Beginning Balance at Dec. 31, 2017	$ 5,944	$ 10,090	$ 380	$ (2,725)	$ (1,896)	$ 5,849	$ 95
Increase (Decrease) in Shareholders' Equity
Common shares issued under share-based compensation plans (in shares)		1,100,000
Common shares issued under share-based compensation plans	1	$ 27	(26)			1
Share-based compensation	65		65			65
Employee withholding taxes related to share-based awards	(10)		(10)			(10)
Noncontrolling interest distributions	(9)						(9)
Net (loss) income	(3,802)			(3,804)		(3,804)	2
Other comprehensive income (loss)	(161)				(157)	(157)	(4)
Ending Balance (in shares) at Sep. 30, 2018		349,800,000
Ending Balance at Sep. 30, 2018	3,237	$ 10,117	409	(5,320)	(2,053)	3,153	84
Beginning Balance (in shares) at Jun. 30, 2018		349,600,000
Beginning Balance at Jun. 30, 2018	3,558	$ 10,114	391	(4,970)	(2,068)	3,467	91
Increase (Decrease) in Shareholders' Equity
Common shares issued under share-based compensation plans (in shares)		200,000
Common shares issued under share-based compensation plans	0	$ 3	(3)
Share-based compensation	22		22			22
Employee withholding taxes related to share-based awards	(1)		(1)			(1)
Noncontrolling interest distributions	(3)						(3)
Net (loss) income	(351)			(350)		(350)	(1)
Other comprehensive income (loss)	12				15	15	(3)
Ending Balance (in shares) at Sep. 30, 2018		349,800,000
Ending Balance at Sep. 30, 2018	$ 3,237	$ 10,117	409	(5,320)	(2,053)	3,153	84
Beginning Balance (in shares) at Dec. 31, 2018	349,871,102	349,900,000
Beginning Balance at Dec. 31, 2018	$ 2,815	$ 10,121	413	(5,664)	(2,137)	2,733	82
Increase (Decrease) in Shareholders' Equity
Common shares issued under share-based compensation plans (in shares)		2,500,000
Common shares issued under share-based compensation plans	3	$ 47	(44)			3
Share-based compensation	77		77			77
Employee withholding taxes related to share-based awards	(40)		(40)			(40)
Noncontrolling interest distributions	(8)						(8)
Net (loss) income	(266)			(272)		(272)	6
Other comprehensive income (loss)	$ (21)				(19)	(19)	(2)
Ending Balance (in shares) at Sep. 30, 2019	352,387,430	352,400,000
Ending Balance at Sep. 30, 2019	$ 2,560	$ 10,168	406	(5,936)	(2,156)	2,482	78
Beginning Balance (in shares) at Jun. 30, 2019		352,200,000
Beginning Balance at Jun. 30, 2019	2,688	$ 10,165	384	(5,887)	(2,061)	2,601	87
Increase (Decrease) in Shareholders' Equity
Common shares issued under share-based compensation plans (in shares)		200,000
Common shares issued under share-based compensation plans	0	$ 3	(3)
Share-based compensation	26		26			26
Employee withholding taxes related to share-based awards	(1)		(1)			(1)
Noncontrolling interest distributions	(8)						(8)
Net (loss) income	(48)			(49)		(49)	1
Other comprehensive income (loss)	$ (97)				(95)	(95)	(2)
Ending Balance (in shares) at Sep. 30, 2019	352,387,430	352,400,000
Ending Balance at Sep. 30, 2019	$ 2,560	$ 10,168	$ 406	$ (5,936)	$ (2,156)	$ 2,482	$ 78

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018
Cash Flows From Operating Activities
Net loss	$ (48)	$ (351)	$ (266)	$ (3,802)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization of intangible assets			1,583	2,273
Amortization and write-off of debt premiums, discounts and issuance costs			49	62
Asset impairments	33	89	49	434
Acquisition-related contingent consideration			2	(23)
Allowances for losses on trade receivable and inventories			46	48
Deferred income taxes			(233)	(2)
(Gain) loss on sale of assets	(1)	26	(10)	26
Additions (reductions) to accrued legal settlements	9	(40)	12	(30)
Payments of accrued legal settlements			(4)	(222)
Goodwill impairments	0	0	0	2,213
Share-based compensation			77	65
Foreign exchange loss (gain)			8	(16)
Loss on extinguishment of debt	0	0	40	75
Payments of contingent consideration adjustments, including accretion			(1)	(2)
Other			27	(19)
Changes in operating assets and liabilities:
Trade receivables			110	56
Inventories			(205)	(8)
Prepaid expenses and other current assets			16	(53)
Accounts payable, accrued and other liabilities			(33)	107
Net cash provided by operating activities			1,267	1,182
Cash Flows From Investing Activities
Acquisition of businesses, net of cash acquired			(180)	5
Payments for intangible and other assets			(1)	(76)
Purchases of property, plant and equipment			(192)	(95)
Purchases of marketable securities			(8)	(5)
Proceeds from sale of marketable securities			3	5
Proceeds from sale of assets and businesses, net of costs to sell			44	32
Net cash used in investing activities			(334)	(134)
Cash Flows From Financing Activities
Net proceeds from the issuances of long-term debt			3,238	7,471
Repayments of long-term debt			(3,956)	(8,200)
Proceeds from the issuances of short-term debt			12	0
Repayments of short-term debt			(12)	(1)
Payments of employee withholding taxes related to share-based awards			(40)	(10)
Payments of acquisition-related contingent consideration			(27)	(26)
Payments of financing costs			(26)	(62)
Payments of deferred consideration			0	(18)
Other			(1)	(5)
Net cash used in financing activities			(812)	(851)
Effect of exchange rate changes on cash and cash equivalents			(17)	(21)
Net increase in cash and cash equivalents and restricted cash			104	176
Cash and cash equivalents and restricted cash, beginning of period			723	797	$ 797
Cash and cash equivalents and restricted cash, end of period	827	973	827	973	723
Cash and cash equivalents						$ 825	$ 721	$ 973
Restricted cash, current						2	2	0
Cash and cash equivalents and restricted cash, end of period	$ 827	$ 973	$ 723	$ 797	$ 723	$ 827	$ 723	$ 973

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the “Company”) is a pharmaceutical and medical device company that develops, manufactures, and markets, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (“OTC”) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Use of Estimates The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S. GAAP that are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 , filed with the U.S. Securities and Exchange Commission (the “SEC”) and the Canadian Securities Administrators on February 20, 2019. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited Consolidated Financial Statements for the year ended December 31, 2018 , except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year. In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted. Principles of Consolidation The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation. Adoption of New Accounting Guidance In February 2016, the Financial Accounting Standards Board ("FASB") issued a new standard revising the accounting for leases to increase transparency and comparability among organizations that lease buildings, equipment and other assets by requiring the recognition of lease assets and lease liabilities on the balance sheet. Under the new standard, all leases are classified as either a finance lease or an operating lease. The classification is determined based on whether substantive control has been transferred to the lessee and its determination will govern the pattern of lease cost recognition. Finance leases are accounted for in substantially the same manner as capital leases under the former U.S. GAAP standard. Operating leases are accounted for in the statements of operations and statements of cash flows in a manner substantially consistent with operating leases under the former U.S. GAAP standard. However, as it relates to the balance sheet, operating lessees are, with limited exception, required to record a right-of-use asset and a corresponding lease liability, equal to the present value of the lease payments for each operating lease. Lessees are not required to recognize a right-of-use asset or lease liability for short-term leases, but instead recognizes lease payments as an expense on a straight-line basis over the lease term. The standard also requires lessees and lessors to provide additional qualitative and quantitative disclosures to help financial statement users assess the amounts, timing and uncertainty of cash flows arising from leases. The Company adopted the new standard effective January 1, 2019, using the modified retrospective approach. Upon adoption, the Company elected the available practical expedients, including: (i) the package of practical expedients as defined in the accounting guidance, which among other things, allowed the carry forward of historical lease classifications, (ii) the election to use hindsight in determining the lease terms for all leases, (iii) the transition method, which does not require the restatement of prior periods, (iv) the election to aggregate lease components with non-lease components and account for these payments as a single lease component and (v) the short-term lease exemption, which does not require recognition on the balance sheet for leases with an initial term of 12 months or less. The Company has updated its systems, processes and controls to track, record and account for its lease portfolio, including implementation of a third-party software tool to assist in complying with the new standard. Upon adoption of the new standard, the Company recognized a right-of-use asset and a corresponding lease liability of $302 million . In addition, approximately $20 million of restructuring liabilities associated with facility closures and deferred rents, included in Other non-current liabilities as of December 31, 2018, were reclassified to reduce right-of-use assets. The adoption of the standard did not have a material impact on the Consolidated Statements of Operations, Comprehensive Loss, Equity and Cash Flows for any of the periods presented. See Note 12, "LEASES" for additional details and application of this standard. In August 2018, the FASB issued guidance aligning the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company has early-adopted this guidance prospectively for all implementation costs incurred after January 1, 2019. Recently Issued Accounting Standards, Not Adopted as of September 30, 2019 In June 2016, the FASB issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods within those annual periods. In May 2019, the FASB issued an update allowing a targeted transition relief for the option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. The Company is evaluating the impact of adoption of this guidance on its financial position, results of operations and cash flows. In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement. The guidance is effective for annual periods beginning after December 15, 2019. The Company is permitted to early-adopt any removed or modified disclosures upon issuance of this update and delay adoption of the additional disclosures until the effective date. The Company is evaluating the impact of adoption of this guidance on its disclosures. In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted. The Company is evaluating the impact of adoption of this guidance on its disclosures.

REVENUE RECOGNITION

REVENUE RECOGNITION	9 Months Ended
	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 20, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. Product Sales Provisions As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities. The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company’s prior estimates, the Company adjusts these estimates when such trends are believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. Over the last several years the Company increased its focus on maximizing operational efficiencies and reducing product returns. The Company continually takes actions to address product returns including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions resulted in improved sales return experience related to current branded products and previously genericized products. As a result, for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018, the provision for sales returns improved by a net of $159 million . Included in the change for the quarters ended September 30, 2019 and 2018, the Company recorded a reduction in variable consideration for sales returns of approximately $80 million and $30 million , respectively, related to past sales. The following tables present the activity and ending balances of the Company’s variable consideration provisions for the nine months ended September 30, 2019 and 2018 . Nine Months Ended September 30, 2019 (in millions) Discounts and Allowances Returns Rebates Chargebacks Distribution Fees Total Reserve balances, January 1, 2019 $ 175 $ 813 $ 1,024 $ 209 $ 163 $ 2,384 Acquisition of Synergy — 3 12 — 1 16 Current period provisions 585 50 1,650 1,425 150 3,860 Payments and credits (583 ) (187 ) (1,673 ) (1,480 ) (181 ) (4,104 ) Reserve balances, September 30, 2019 $ 177 $ 679 $ 1,013 $ 154 $ 133 $ 2,156 Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $26 million and $26 million as of September 30, 2019 and January 1, 2019, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits for the nine months ended September 30, 2019 . Nine Months Ended September 30, 2018 (in millions) Discounts and Allowances Returns Rebates Chargebacks Distribution Fees Total Reserve balances, January 1, 2018 $ 167 $ 863 $ 1,094 $ 274 $ 148 $ 2,546 Current period provisions 643 209 1,976 1,462 178 4,468 Payments and credits (632 ) (264 ) (1,939 ) (1,512 ) (167 ) (4,514 ) Reserve balances, September 30, 2018 $ 178 $ 808 $ 1,131 $ 224 $ 159 $ 2,500 Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $29 million as of September 30, 2018 , which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $15 million for the nine months ended September 30, 2018 . Contract Assets and Contract Liabilities There are no

ACQUISITION AND ASSETS HELD FOR

ACQUISITION AND ASSETS HELD FOR SALE	9 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
ACQUISITION AND ASSETS HELD FOR SALE	ACQUISITION AND ASSETS HELD FOR SALE Acquisition On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance ® (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies. Assets Acquired and Liabilities Assumed The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date: (in millions) Accounts receivable $ 7 Inventories 24 Prepaid expenses and other current assets 5 Product brand intangible assets (estimated useful life - 7 years) 159 Accounts payable (1 ) Accrued expenses (17 ) Total identifiable net assets 177 Goodwill 3 Total fair value of consideration transferred $ 180 Due to the timing of the acquisition, the following are provisional and are subject to change: • amounts for intangible assets, property and equipment, inventories, receivables and other working capital adjustments pending finalization of the valuation; • amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction; and • amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed. The Company will finalize these amounts no later than one year from the acquisition date, once it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in adjustments to the provisional amounts recognized at the acquisition date which will impact the reported results in the period those adjustments are identified. These adjustments, if any, could be material. Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes. Revenue and Operating Results Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through September 30, 2019 were $37 million . Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through September 30, 2019 and pro-forma revenues and operating results for the nine months ended September 30, 2019 and 2018 were not material. Included in Other expense (income), net during the nine months ended September 30, 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services. Assets Held for Sale The Company has identified certain products for disposal as of September 30, 2019. The products and the related assets and liabilities of this disposal group qualify as a business. Revenues associated with this business were $11 million and $19 million for the nine months ended September 30, 2019 and the year ended December 31, 2018, respectively. The carrying value of the business, including inventories, intangible assets, goodwill and deferred income taxes, was adjusted to its estimated fair value less costs to sell and reclassified as held for sale as of September 30, 2019. Included in Asset impairments in the Consolidated Statement of Operations during the three and nine months ended September 30, 2019 , is an impairment of $8 million associated with this business.

RESTRUCTURING AND INTEGRATION C

RESTRUCTURING AND INTEGRATION COSTS	9 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND INTEGRATION COSTS	RESTRUCTURING AND INTEGRATION COSTS The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses. The expenses associated with the implementation of these cost savings programs include expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of September 30, 2019 was $28 million . During the nine months ended September 30, 2019 , the Company incurred $28 million of restructuring and integration costs. These costs included: (i) $11 million of severance and other costs associated with the acquisition of certain assets of Synergy , (ii) $9 million of facility closure costs and (iii) $8 million of other severance costs. The Company made payments of $27 million for the nine months ended September 30, 2019 . During the nine months ended September 30, 2018 , the Company incurred $16 million of restructuring and integration costs. These costs included: (i) $8 million of severance costs and (ii) $8 million of facility closure costs. The Company made payments of $29 million for the nine months ended September 30, 2018 .

FAIR VALUE MEASUREMENTS AND FIN

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS	FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS Fair value measurements are estimated based on valuation techniques and inputs categorized as follows: • Level 1 — Quoted prices in active markets for identical assets or liabilities; • Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis: September 30, 2019 December 31, 2018 (in millions) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 284 $ 250 $ 34 $ — $ 197 $ 166 $ 31 $ — Restricted cash $ 2 $ 2 $ — $ — $ 2 $ 2 $ — $ — Cross-currency swaps $ 8 $ — $ 8 $ — $ — $ — $ — $ — Liabilities: Acquisition-related contingent consideration $ 313 $ — $ — $ 313 $ 339 $ — $ — $ 339 Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. There were no transfers between Level 1, Level 2 or Level 3 during the nine months ended September 30, 2019 . Cross-currency Swaps During the third quarter of 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million , to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company’s investment in certain euro-denominated subsidiaries. Prior to the third quarter of 2019, the Company had no derivative instruments for any period presented. The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period. The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the risk free interest rate and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps, is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the three and nine-month periods ended September 30, 2019. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations. The fair value of the Company’s cross-currency swaps asset at September 30, 2019 was $8 million and is included in Other non-current assets within the Consolidated Balance Sheets. The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations: Gain recognized in Other Comprehensive Loss Gain excluded from assessment of hedge effectiveness Location of gain in income of excluded component (in millions) Three Months Ended Nine Months Ended Three Months Ended Nine Months Ended Cross-currency swaps $ 5 $ 5 $ 3 $ 3 Interest expense During the nine months ended September 30, 2019, there were no payments or receipts in settlement of the Company’s cross-currency swaps as the settlement dates occur in February and August of each year, with the first settlement in February 2020. Future settlements of the Company’s cross-currency swaps will be reported as investing activities in the Consolidated Statement of Cash Flows. Acquisition-related Contingent Consideration Obligations The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level 3) inputs. These inputs may include: (i) the estimated amount and timing of projected cash flows, (ii) the probability of the achievement of the factor(s) on which the contingency is based and (iii) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At September 30, 2019 , the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 5% to 25% . The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the nine months ended September 30, 2019 and 2018 : (in millions) 2019 2018 Balance, beginning of period $ 339 $ 387 Adjustments to Acquisition-related contingent consideration: Accretion for the time value of money $ 16 $ 18 Fair value adjustments due to changes in estimates of other future payments (14 ) (41 ) Acquisition-related contingent consideration 2 (23 ) Payments (28 ) (28 ) Balance, end of period 313 336 Current portion included in Accrued and other current liabilities 46 54 Non-current portion $ 267 $ 282 Included in Fair value adjustments due to changes in estimates of other future payments in the table above for the nine months ended September 30, 2019 , is an $8 million fair value adjustment related to an acquisition which occurred in 2011. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis: September 30, 2019 December 31, 2018 (in millions) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Other non-current assets: Non-current assets held for sale $ 39 $ — $ — $ 39 $ — $ — $ — $ — Non-current assets held for sale of $39 million included in the Consolidated Balance Sheets as of September 30, 2019 were remeasured to estimated fair values less costs to sell. Included in Asset impairments for the three and nine months ended September 30, 2019 , is a charge of $8 million associated with these assets held for sale. The estimated fair values of these assets less costs to sell were determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. See Note 4, "ACQUISITION AND ASSETS HELD FOR SALE" for additional details regarding these assets held for sale. Fair Value of Long-term Debt The fair value of long-term debt as of September 30, 2019 and December 31, 2018 was $25,005 million and $23,357 million , respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2) .

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories, net of allowances for obsolescence consist of: (in millions) September 30, December 31, Raw materials $ 317 $ 275 Work in process 171 95 Finished goods 612 564 $ 1,100 $ 934

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	INTANGIBLE ASSETS AND GOODWILL Intangible Assets The major components of intangible assets consist of: September 30, 2019 December 31, 2018 (in millions) Gross Carrying Amount Accumulated Amortization and Impairments Net Carrying Amount Gross Carrying Amount Accumulated Amortization and Impairments Net Carrying Amount Finite-lived intangible assets: Product brands $ 20,963 $ (13,125 ) $ 7,838 $ 20,891 $ (11,958 ) $ 8,933 Corporate brands 925 (317 ) 608 926 (263 ) 663 Product rights/patents 3,292 (2,828 ) 464 3,292 (2,658 ) 634 Partner relationships 159 (157 ) 2 168 (166 ) 2 Technology and other 206 (183 ) 23 208 (173 ) 35 Total finite-lived intangible assets 25,545 (16,610 ) 8,935 25,485 (15,218 ) 10,267 Acquired IPR&D not in service 17 — 17 36 — 36 Bausch + Lomb Trademark 1,698 — 1,698 1,698 — 1,698 $ 27,260 $ (16,610 ) $ 10,650 $ 27,219 $ (15,218 ) $ 12,001 Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. Asset impairments for the nine months ended September 30, 2019 include impairments of: (i) $38 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale and (iii) $3 million , in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses. Asset impairments for the nine months ended September 30, 2018 include impairments of: (i) $341 million reflecting decreases in forecasted sales for the Uceris ® Tablet product and other product lines due to generic competition, (ii) $60 million , in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and revisions to forecasted sales, (iii) $28 million to Acquired IPR&D not in service related to a certain product and (iv) $5 million related to assets being classified as held for sale. Periodically, the Company’s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such products would decrease shortly following a loss of exclusivity, due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company’s own branded generic or through a third-party). This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material. As a result of the launch of a generic competitor in July 2018, the Company revised its near and long-term financial projections of the Uceris ® Tablet related intangible assets. As of June 30, 2018, the carrying value of the Uceris ® Tablet related intangible assets exceeded the undiscounted expected cash flows from the Uceris ® Tablet. As a result, the Company recognized an impairment of $263 million to reduce the carrying value of the Uceris ® Tablet related intangible assets to their estimated fair value. As of September 30, 2019 , the remaining carrying value of the Uceris ® Tablet related intangible assets was $70 million . Prior to its launch, the Company initiated infringement proceedings against this generic competitor. The Company continues to believe that its Uceris ® Tablet-related patents are enforceable and is proceeding in the ongoing litigation between the Company and the generic competitor, however the ultimate outcome of the matter is not predictable. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions. In review of the Company’s finite-lived intangible assets, management revised the estimated useful lives of certain intangible assets in 2018. Effective September 12, 2018, the Company changed the estimated useful life of its Xifaxan ® -related intangible assets due to the positive impact of the agreement between the Company and Actavis Laboratories FL, Inc. ("Actavis") resolving the intellectual property litigation regarding Xifaxan ® tablets, 550 mg. As discussed in further detail in Note 20, "LEGAL PROCEEDINGS" to the Company's Annual Consolidated Financial Statements contained in its Annual Report on Form 10-K for the year ended December 31, 2018, the parties agreed to dismiss all litigation related to Xifaxan ® tablets, 550 mg and all intellectual property protecting Xifaxan ® will remain intact and enforceable. As a result, the useful life of the Xifaxan ® -related intangible assets was extended from 2024 to January 1, 2028. As this change in the estimated useful life is a change in an accounting estimate, amortization expense is impacted prospectively. The change in the estimated useful life of the Xifaxan ® -related intangible assets resulted in a decrease to the Net loss attributable to Bausch Health Companies Inc. of $353 million , and a decrease to the Basic and Diluted Loss per share attributable to Bausch Health Companies Inc. of $1.00 for the nine months ended September 30, 2019 . As of September 30, 2019 , the net carrying value of the Xifaxan ® -related intangible assets was $4,444 million . Estimated amortization expense of finite-lived intangible assets for the remainder of 2019 and each of the five succeeding years ending December 31 and thereafter is as follows: (in millions) Remainder of 2019 2020 2021 2022 2023 2024 Thereafter Total Amortization $ 444 $ 1,623 $ 1,374 $ 1,224 $ 1,080 $ 952 $ 2,238 $ 8,935 Goodwill The changes in the carrying amounts of goodwill during the nine months ended September 30, 2019 and the year ended December 31, 2018 were as follows: (in millions) Bausch + Lomb/ International Branded Rx U.S. Diversified Products Salix Ortho Dermatologics Diversified Products Total Balance, January 1, 2018 $ 6,016 $ 6,631 $ 2,946 $ — $ — $ — $ 15,593 Impairment of the Salix and Ortho Dermatologics reporting units — (2,213 ) — — — — (2,213 ) Realignment of Global Solta reporting unit goodwill (82 ) 115 (33 ) — — — — Goodwill reclassified to assets held for sale and subsequently disposed (2 ) — — — — — (2 ) Realignment of segment goodwill — (4,533 ) (2,913 ) 3,156 1,267 3,023 — Impairment of the Dentistry reporting unit — — — — — (109 ) (109 ) Foreign exchange and other (127 ) — — — — — (127 ) Balance, December 31, 2018 5,805 — — 3,156 1,267 2,914 13,142 Acquisition of certain assets of Synergy — — — 3 — — 3 Goodwill reclassified to assets held for sale (Note 4) (18 ) — — — — — (18 ) Foreign exchange and other (75 ) — — — — — (75 ) Balance, September 30, 2019 $ 5,712 $ — $ — $ 3,159 $ 1,267 $ 2,914 $ 13,052 Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of all reporting units using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The Company performed its annual impairment test as of October 1, 2018, utilizing long-term growth rates for its reporting units ranging from 1.0% to 3.0% and discount rates applied to the estimated cash flows ranging from 7.5% to 14.0% in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. The Company forecasts cash flows for each reporting unit and takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts were based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company’s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future. 2018 Adoption of New Accounting Guidance for Goodwill Impairment Testing In January 2017, the FASB issued guidance which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. The Company elected to adopt this guidance effective January 1, 2018. Upon adopting the new guidance, the Company tested goodwill for impairment and determined that the carrying value of the Salix reporting unit exceeded its fair value. As a result of the adoption of new accounting guidance, the Company recognized a goodwill impairment of $1,970 million associated with the Salix reporting unit. As of October 1, 2017, the date of the 2017 annual goodwill impairment test, the fair value of the Ortho Dermatologics reporting unit exceeded its carrying value. However, at January 1, 2018, unforeseen changes in the business dynamics of the Ortho Dermatologics reporting unit, such as: (i) changes in the dermatology sector, (ii) increased pricing pressures from third-party payors, (iii) additional risks to the exclusivity of certain products and (iv) an expected longer launch cycle for a new product, were factors that negatively impacted the reporting unit's operating results beyond management's expectations as of October 1, 2017, when the Company performed its 2017 annual goodwill impairment test. In response to these adverse business indicators, as of January 1, 2018, the Company reduced its near and long term financial projections for the Ortho Dermatologics reporting unit. As a result of the reductions in the near and long term financial projections, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at January 1, 2018 and the Company recognized a goodwill impairment of $243 million . 2018 Realignment of Solta Business Effective March 1, 2018, revenues and profits from the U.S. Solta business included in the former U.S. Diversified Products segment in prior periods and revenues and profits from the international Solta business included in the Bausch + Lomb/International segment in prior periods, are reported in the new Global Solta reporting unit, which, at that time, was a part of the former Branded Rx segment. As a result of this change, $115 million of goodwill was reallocated to the new Global Solta reporting unit and the Company assessed the impact on the fair values of each of the reporting units affected. After considering, among other matters: (i) the limited period of time between last impairment test (January 1, 2018) and the realignment (March 1, 2018), (ii) the results of the last impairment test and (iii) the amount of goodwill reallocated to the new Global Solta reporting unit, the Company did not identify any indicators of impairment at the time of the realignment. 2018 Realignment of Segment Structure In the second quarter of 2018, the Company began operating in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. The Bausch + Lomb/International segment consists of the: (i) U.S. Bausch + Lomb and (ii) International reporting units. The Salix segment consists of the Salix reporting unit. The Ortho Dermatologics segment consists of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. There was no triggering event which would require the Company to test goodwill for impairment as a result of the second quarter realignment of the segment structure as it did not result in a change in the reporting units. 2018 Annual Goodwill Impairment Test The Company conducted its annual goodwill impairment test as of October 1, 2018 and determined that the carrying value of the Dentistry reporting unit exceeded its fair value and, as a result, the Company recognized a goodwill impairment of $109 million for the Dentistry reporting unit, representing the full amount of goodwill for the reporting unit. Changing market conditions such as: (i) an increasing competitive environment and (ii) increasing pricing pressures negatively impacted the reporting unit's operating results. The Company is taking steps to address these changing market and business conditions. The Company's remaining reporting units passed the goodwill impairment test as the estimated fair value of each reporting unit exceeded its carrying value at the date of testing and, therefore, there was no impairment to goodwill for any reporting unit other than the Dentistry reporting unit. In order to evaluate the sensitivity of its fair value calculations on the goodwill impairment test, the Company compared the carrying value of each reporting unit to its fair value as of October 1, 2018, the date of testing. As of October 1, 2018, the fair value of each reporting unit with associated goodwill exceeded its carrying value by more than 15%. 2019 Interim Goodwill Impairment Assessment No events occurred or circumstances changed during the period October 1, 2018 (the date goodwill was last tested for impairment) through September 30, 2019 that would indicate that the fair value of any reporting unit might be below its carrying value. Based on the results of the October 1, 2018 annual goodwill impairment test, the Company continues to perform qualitative interim assessments of the carrying value and fair value of the Ortho Dermatologics reporting unit on a quarterly basis to determine if impairment testing of goodwill will be warranted. As part of the qualitative assessment as of September 30, 2019, management compared the reporting unit’s operating results to the forecast used to test the goodwill of the Ortho Dermatologics reporting unit as of October 1, 2018. Based on the qualitative assessment, management believed that the carrying value of Ortho Dermatologics reporting unit did not exceed its fair value and, therefore, concluded a quantitative assessment was not required at September 30, 2019. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges can be material. Accumulated goodwill impairment charges through September 30, 2019 were $3,711 million .

ACCRUED AND OTHER CURRENT LIABI

ACCRUED AND OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
ACCRUED AND OTHER CURRENT LIABILITIES	ACCRUED AND OTHER CURRENT LIABILITIES Accrued and other current liabilities consist of: (in millions) September 30, December 31, 2018 Product rebates $ 987 $ 998 Product returns 679 813 Interest 388 273 Employee compensation and benefit costs 291 301 Income taxes payable 150 167 Other 703 645 $ 3,198 $ 3,197

FINANCING ARRANGEMENTS

FINANCING ARRANGEMENTS	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
FINANCING ARRANGEMENTS	FINANCING ARRANGEMENTS Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: September 30, 2019 December 31, 2018 (in millions) Maturity Principal Amount Net of Premiums, Discounts and Issuance Costs Principal Amount Net of Premiums, Discounts and Issuance Costs Senior Secured Credit Facilities: 2023 Revolving Credit Facility June 2023 $ — $ — $ 75 $ 75 June 2025 Term Loan B Facility June 2025 3,932 3,826 4,394 4,269 November 2025 Term Loan B Facility November 2025 1,312 1,293 1,481 1,456 Senior Secured Notes: 6.50% Secured Notes March 2022 1,250 1,241 1,250 1,239 7.00% Secured Notes March 2024 2,000 1,982 2,000 1,979 5.50% Secured Notes November 2025 1,750 1,732 1,750 1,730 5.75% Secured Notes August 2027 500 493 — — Senior Unsecured Notes: 5.625% December 2021 — — 700 697 5.50% March 2023 402 400 1,000 995 5.875% May 2023 1,548 1,540 3,250 3,229 4.50% euro-denominated debt May 2023 1,635 1,626 1,720 1,709 6.125% April 2025 3,250 3,229 3,250 3,226 9.00% December 2025 1,500 1,472 1,500 1,469 9.25% April 2026 1,500 1,484 1,500 1,482 8.50% January 2027 1,750 1,756 750 738 7.00% January 2028 750 740 — — 7.25% May 2029 750 740 — — Other Various 12 12 12 12 Total long-term debt and other $ 23,841 23,566 $ 24,632 24,305 Less: Current portion of long-term debt and other 100 228 Non-current portion of long-term debt $ 23,466 $ 24,077 Covenant Compliance The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company’s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00 :1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill. As of September 30, 2019 , the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company’s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate. Senior Secured Credit Facilities On February 13, 2012, the Company and certain of its subsidiaries as guarantors entered into the “Senior Secured Credit Facilities” under the Company’s Third Amended and Restated Credit and Guaranty Agreement, as amended (the “Third Amended Credit Agreement”) with a syndicate of financial institutions and investors, as lenders. As of January 1, 2018, the Third Amended Credit Agreement, as amended, provided for: (i) $1,500 million of revolving credit facilities, which included a sublimit for the issuance of standby and commercial letters of credit and a sublimit for swing line loans and (ii) a series of tranche B term loans maturing on April 1, 2022 (the "Series F Tranche B Term Loan Facility"). On June 1, 2018, the Company entered into the Restated Credit Agreement. The Restated Credit Agreement amended and restated in full the Third Amended Credit Agreement. The Restated Credit Agreement replaced the 2020 Revolving Credit Facility with a revolving credit facility of $1,225 million (the "2023 Revolving Credit Facility") and replaced the Series F Tranche B Term Loan Facility principal amount outstanding of $3,315 million with a seven year Tranche B Term Loan Facility of $4,565 million (the “ June 2025 Term Loan B Facility ”) borrowed by the Company’s subsidiary, Bausch Health Americas, Inc. ("BHA") (formerly Valeant Pharmaceuticals International). The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $1,000 million . Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars, Canadian dollars or euros. On June 1, 2018, the Company issued an irrevocable notice of redemption for the remaining outstanding principal amounts of: (i) $691 million of 5.375% Senior Unsecured Notes due 2020 (the "March 2020 Unsecured Notes"), (ii) $578 million of 6.75% Senior Unsecured Notes due 2021(the "August 2021 Unsecured Notes"), (iii) $550 million of 7.25% Senior Unsecured Notes due 2022 (the “July 2022 Unsecured Notes”) and (iv) $146 million of 6.375% Senior Unsecured Notes due 2020 (the “ 6.375% October 2020 Unsecured Notes” and together with the March 2020 Unsecured Notes, August 2021 Unsecured Notes and July 2022 Unsecured Notes the “June 2018 Unsecured Refinanced Debt”). On June 1, 2018, using the remaining net proceeds from the June 2025 Term Loan B Facility , the net proceeds from the issuance of $750 million in aggregate principal amount of 8.50% Senior Unsecured Notes due 2027 (the "January 2027 Unsecured Notes") by BHA and cash on hand, the Company prepaid the remaining Series F Tranche B Term Loan Facility and redeemed the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged (collectively, the “ June 2018 Refinancing Transactions ”). In connection with the Restated Credit Agreement, the Company incurred a loss on extinguishment of debt of $48 million . Certain payments made to the lenders and third parties of $74 million associated with the Restated Credit Agreement were capitalized and are being amortized as interest expense over the remaining terms of the debt. Third-party expenses of $4 million were expensed as Interest expense. On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional seven year Tranche B Term Loan Facility of $1,500 million (the " November 2025 Term Loan B Facility ") and used the net proceeds, and cash on hand, to repay $1,483 million of 7.50% Senior Unsecured Notes due July 2021 (the “ July 2021 Unsecured Notes ”) in a tender offer (the " November 2018 Refinancing Transactions "). On December 27, 2018, the Company redeemed, using cash on hand, the remaining outstanding principal amount of $17 million of the July 2021 Unsecured Notes . In connection with the repayment of the July 2021 Unsecured Notes , the Company incurred a loss on extinguishment of debt of $43 million . Certain payments made to the lenders and third parties of $25 million associated with the issuance of the November 2025 Term Loan B Facility were capitalized and are being amortized as interest expense over the remaining term of the November 2025 Term Loan B Facility . As of September 30, 2019 , the Company had no outstanding borrowings, $170 million of issued and outstanding letters of credit and remaining availability of $1,055 million under its 2023 Revolving Credit Facility. During October 2019, the Company had drawn net borrowings of $200 million under its 2023 Revolving Credit Facility. Current Description of Senior Secured Credit Facilities Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% and (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00% ) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin. Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin. Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the “Canadian Prime Rate” or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00% ) or (ii) the bankers’ acceptance rate for Canadian dollar deposits in the Toronto interbank market (the “BA rate”) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin. Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization. The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75% , respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75% , respectively, with respect to eurocurrency rate and BA rate borrowings. As of September 30, 2019 , the stated rates of interest on the Company’s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 5.04% and 4.79% per annum, respectively. The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of September 30, 2019 , the remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities were $1,226 million through November 1, 2025. The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50% - 2.00% with respect to base rate or prime rate borrowings and 2.50% - 3.00% with respect to eurocurrency rate or BA rate borrowings. As of September 30, 2019 , the stated rate of interest on the 2023 Revolving Credit Facility was 5.04% per annum. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees. The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50 :1.00. Senior Secured Notes The Senior Secured Notes are guaranteed by each of the Company’s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the “Note Guarantors”). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company’s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company’s and Note Guarantors’ respective existing and future unsubordinated indebtedness and senior to the Company’s and Note Guarantors’ respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively pari passu with the Company’s and the Note Guarantors’ respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company’s and the Note Guarantors’ respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company’s debt that is secured by assets that are not collateral. Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder’s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest. 5.75% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of January 2027 Unsecured Notes and (ii) $500 million aggregate principal amount of 5.75% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement, a portion of the net proceeds of which, and cash on hand, were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the “December 2021 Unsecured Notes”), (iii) repurchase $216 million of 5.50% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes”) and (iv) pay all fees and expenses associated with these transactions (collectively, the “ March 2019 Refinancing Transactions ”). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions . The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15. The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture. Senior Unsecured Notes The Senior Unsecured Notes issued by the Company are the Company’s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest. 9.25% Senior Unsecured Notes due 2026 - March 2018 Refinancing Transactions On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.25% Senior Unsecured Notes due 2026 (the “April 2026 Unsecured Notes”) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes, which consisted of: (i) $1,017 million in principal amount of the March 2020 Unsecured Notes, (ii) $411 million in principal amount of the 6.375% October 2020 Unsecured Notes and (iii) $72 million in principal amount of the August 2021 Unsecured Notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the “ March 2018 Refinancing Transactions ”). The March 2018 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $26 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. The April 2026 Unsecured Notes accrue interest at the rate of 9.25% per year, payable semi-annually in arrears on each of April 1 and October 1. 8.50% Senior Unsecured Notes due 2027 - June 2018 Refinancing Transactions and March 2019 Refinancing Transactions As part of the June 2018 Refinancing Transactions , BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement, the proceeds of which, when combined with the remaining net proceeds from the June 2025 Term Loan B Facility and cash on hand, were deposited with The Bank of New York Mellon Trust Company, N.A., as trustee under the indentures governing the June 2018 Unsecured Refinanced Debt, to redeem the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged. The January 2027 Unsecured Notes accrue interest at the rate of 8.50% per year, payable semi-annually in arrears on each of January 31 and July 31. As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of 8.50% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA’s existing January 2027 Unsecured Notes. 7.00% Senior Unsecured Notes due 2028 and 7.25% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.00% Senior Unsecured Notes due January 2028 (the "January 2028 Unsecured Notes") and (ii) $750 million aggregate principal amount of 7.25% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement, the net proceeds of which, and cash on hand, were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the “ May 2019 Refinancing Transactions ”). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $32 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. The January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to 40% of the aggregate principal amount of the January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. Weighted Average Stated Rate of Interest The weighted average stated rate of interest for the Company's outstanding debt obligations as of September 30, 2019 and December 31, 2018 was 6.39% and 6.23% , respectively. Maturities and Mandatory Payments Maturities and mandatory payments of debt obligations for the remainder of 2019 , the five succeeding years ending December 31 and thereafter are as follows: (in millions) Remainder of 2019 $ 100 2020 — 2021 203 2022 1,553 2023 3,788 2024 2,303 Thereafter 15,894 Total debt obligations 23,841 Unamortized premiums, discounts and issuance costs (275 ) Total long-term debt and other $ 23,566 During October 2019, the Company (i) repaid $100 million aggregate principal amount of its outstanding 5.875% Senior Notes due 2023 and (ii) had drawn net borrowings of $200 million under its 2023 Revolving Credit Facility. These transactions are not reflected in the table above.

PENSION AND POSTRETIREMENT EMPL

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS	9 Months Ended
	Sep. 30, 2019
Retirement Benefits [Abstract]
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS	PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2019 and 2018 consists of: Pension Benefit Plans Postretirement U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2019 2018 2019 2018 Service cost $ 1 $ 1 $ 2 $ 2 $ — $ — Interest cost 6 5 4 4 1 1 Expected return on plan assets (10 ) (11 ) (4 ) (4 ) — — Amortization of prior service credit — — (1 ) (1 ) (2 ) (2 ) Amortization of net loss — — 1 1 — — Net periodic (benefit) cost $ (3 ) $ (5 ) $ 2 $ 2 $ (1 ) $ (1 )

LEASES

LEASES	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
LEASES	LEASES The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of one to twenty years , some of which include termination options and options to extend the lease term from one to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants. As discussed in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" under the new standard for accounting for leases, which the Company adopted effective January 1, 2019, the Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term. All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee. The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable. As of September 30, 2019 , the Company's finance leases were not material. Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of September 30, 2019 as follows: (in millions) Right-of-use assets included in: Other non-current assets $ 263 Lease liabilities included in: Accrued and other current liabilities $ 49 Other non-current liabilities 235 Total lease liabilities $ 284 Sub-lease income is not material. Lease expense includes: (in millions) Three Months Ended Nine Months Ended Operating lease costs $ 15 $ 47 Variable operating lease costs $ 3 $ 12 Short-term lease expense $ 1 $ 2 Other information related to operating leases for the nine months ended September 30, 2019 is as follows: (dollars in millions) Cash paid from operating cash flows for amounts included in the measurement of lease liabilities $ 56 Right-of-use assets obtained in exchange for new operating lease liabilities $ 28 Weighted-average remaining lease term 8.5 years Weighted-average discount rate 6.2 % Right-of-use assets obtained in exchange for new operating lease liabilities during the nine months ended September 30, 2019 of $28 million in the table above does not include $282 million of right-of-use assets recognized upon adoption of the new standard for accounting for leases on January 1, 2019. See Note 2, "SIGNIFICANT ACCOUNTING POLICIES" for further detail regarding the impact of adoption. As of September 30, 2019 , future payments under noncancelable operating leases for the remainder of 2019, each of the five succeeding years ending December 31 and thereafter are as follows: (in millions) Remainder of 2019 $ 16 2020 63 2021 49 2022 39 2023 34 2024 28 Thereafter 146 Total 375 Less: Imputed interest 91 Present value of remaining lease payments 284 Less: Current portion 49 Non-current portion $ 235 Upon adopting the new lease guidance, the Company elected the modified retrospective approach without revising prior periods. Accordingly, the Company is providing the following table of future payments under noncancelable operating leases as of December 31, 2018, for each of the five succeeding years ending December 31 and thereafter as previously disclosed under prior accounting guidance: (in millions) 2019 2020 2021 2022 2023 Thereafter Total Future payments $ 78 $ 60 $ 44 $ 39 $ 32 $ 166 $ 419

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION In May 2014, shareholders approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”) which replaced the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan is equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company’s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan. Effective April 30, 2018, the Company amended and restated the 2014 Plan (the “Amended and Restated 2014 Plan”). The Amended and Restated 2014 Plan included the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan was increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address changes to Section 162(m) of the Internal Revenue Code, (iv) awards were made expressly subject to the Company’s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis. Approximately 9,916,000 common shares were available for future grants as of September 30, 2019 . The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans. During the three months ended March 31, 2017, the Company introduced a long-term incentive program with the objective to re-align the share-based awards granted to senior management with the Company’s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (“RSUs”) and performance-based RSUs. Performance-based RSUs are comprised of awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (“TSR”) and awards that vest upon attainment of certain performance targets that are based on the Company’s return on tangible capital (“ROTC”). The following table summarizes the components and classification of share-based compensation expense related to stock options and RSUs for the three and nine months ended September 30, 2019 and 2018 : Three Months Ended Nine Months Ended (in millions) 2019 2018 2019 2018 Stock options $ 5 $ 6 $ 17 $ 17 RSUs 21 16 60 48 $ 26 $ 22 $ 77 $ 65 Research and development expenses $ 2 $ 3 $ 7 $ 7 Selling, general and administrative expenses 24 19 70 58 $ 26 $ 22 $ 77 $ 65 Share-based awards granted consist of: Nine Months Ended September 30, 2019 2018 Stock options Granted 1,725,000 2,106,000 Weighted-average exercise price $ 23.16 $ 15.46 Weighted-average grant date fair value $ 8.46 $ 7.82 Time-based RSUs Granted 2,895,000 2,844,000 Weighted-average grant date fair value $ 23.93 $ 17.36 TSR performance-based RSUs Granted 454,000 469,000 Weighted-average grant date fair value $ 34.53 $ 29.35 ROTC performance-based RSUs Granted 505,000 409,000 Weighted-average grant date fair value $ 25.03 $ 18.80 The granted stock options, time-based RSUs and performance-based RSUs includes long-term incentive awards granted to the Company’s Chief Executive Officer ("CEO") during the three months ended March 31, 2018, which had an aggregate value of $10 million . In connection with his 2018 award, approximately 933,000 performance-based RSUs received by the CEO upon his hire in 2016 were cancelled, and the shares underlying those performance-based RSUs were permanently retired and are not available for future grants under the Amended and Restated 2014 Plan. The CEO's long-term incentive award was accounted for as an award modification whereby the Company continues to recognize the unamortized compensation associated with the original award plus the incremental fair value of the new award measured at the date of grant, over the vesting period of the new award. As of September 30, 2019 , the remaining unrecognized compensation expense related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $119 million , which will be amortized over a weighted-average period of 1.71 years.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE LOSS	9 Months Ended
	Sep. 30, 2019
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	ACCUMULATED OTHER COMPREHENSIVE LOSS Accumulated other comprehensive loss consists of: (in millions) September 30, December 31, Foreign currency translation adjustments $ (2,129 ) $ (2,111 ) Pension and postretirement benefit plan adjustments, net of tax (27 ) (26 ) $ (2,156 ) $ (2,137 ) Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company’s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company’s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested. During the three and nine months ended September 30, 2019, amounts reclassified from Accumulated other comprehensive loss into the Company's operating results were no t material.

RESEARCH AND DEVELOPMENT

RESEARCH AND DEVELOPMENT	9 Months Ended
	Sep. 30, 2019
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of: Three Months Ended Nine Months Ended (in millions) 2019 2018 2019 2018 Product related research and development $ 114 $ 98 $ 329 $ 265 Quality assurance 9 9 28 28 $ 123 $ 107 $ 357 $ 293

OTHER EXPENSE (INCOME), NET

OTHER EXPENSE (INCOME), NET	9 Months Ended
	Sep. 30, 2019
Other Income and Expenses [Abstract]
OTHER EXPENSE (INCOME), NET	OTHER EXPENSE (INCOME), NET Other expense (income), net consists of: Three Months Ended Nine Months Ended (in millions) 2019 2018 2019 2018 Net (gain) loss on sale of assets $ (1 ) $ 26 $ (10 ) $ 26 Acquisition-related costs — — 8 1 Litigation and other matters 9 (40 ) 12 (30 ) Other, net 2 (1 ) 5 — $ 10 $ (15 ) $ 15 $ (3 ) Included in Other, net in the table above for the nine months ended September 30, 2019 , is $9 million of in-process research and development costs associated with the upfront payments to enter into certain exclusive licensing agreements.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company's ordinary income, subject to certain limitations on the benefit of losses. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company's income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company's estimated annual effective income tax rate may be revised, if necessary, in each interim period. Benefit from income taxes for the nine months ended September 30, 2019 was $101 million and included: (i) $46 million of net income tax benefit for discrete items, which includes: (a) a $32 million tax benefit recognized upon a ruling from the Polish tax authorities confirming the deductibility of royalty payments by an affiliate, (b) $13 million in tax benefits associated with the filing of certain tax returns and (c) $1 million of net tax charges related to other changes in uncertain tax positions and (ii) $55 million of income tax benefit for the Company's ordinary loss during the nine months ended September 30, 2019 . Provision for income taxes for the nine months ended September 30, 2018 was $74 million and included: (i) $203 million of net income tax expense for discrete items, which includes: (a) $255 million of tax charges related to internal restructurings and (b) a $57 million tax benefit related to the impairment of intangible assets and (ii) $129 million of income tax benefit for the Company's ordinary loss during the nine months ended September 30, 2018 . The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made except that, as a result of the 2018 adoption of guidance regarding intra-entity transfers, any change in valuation allowance surrounding the adoption of the intra-entity transfer resulting from this adoption was recorded within equity. The valuation allowance against deferred tax assets was $3,126 million and $2,913 million as of September 30, 2019 and December 31, 2018 , respectively. The increase was primarily due to continued losses in Canada. The Company will continue to assess the need for a valuation allowance on a go-forward basis. As of September 30, 2019 and December 31, 2018 , the Company had $622 million and $654 million of unrecognized tax benefits, which included $48 million and $42 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of September 30, 2019 , $316 million would reduce the Company’s effective tax rate, if recognized. The Company anticipates that unrecognized tax benefits resolved within the next 12 months will not be material. The Company continues to be under examination by the Canada Revenue Agency. The Company’s position as of September 30, 2019 with regard to proposed audit adjustments has not changed and the proposed adjustments continue to result primarily in a loss of tax attributes that are subject to a full valuation allowance. The Internal Revenue Service completed its examinations of the Company’s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations. The Company has filed tax returns which used a capital loss generated in 2017 to offset capital gains generated in 2014. As these tax returns were filed subsequent to the commencement of the examination by the Internal Revenue Service, the Company’s 2014 tax year cannot be closed commensurate with the examination’s conclusion. Additionally, the Internal Revenue Service has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. At this time, the Company does not expect that proposed adjustments, if any, for these periods would be material to the Company's consolidated financial statements. The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2012 through 2017. The Company’s subsidiaries in Germany are under audit for tax years 2013 through 2017. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's consolidated financial statements. The Company’s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's consolidated financial statements. Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's consolidated financial statements.

LOSS PER SHARE

LOSS PER SHARE	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
LOSS PER SHARE	LOSS PER SHARE Loss per share attributable to Bausch Health Companies Inc. were calculated as follows: Three Months Ended Nine Months Ended (in millions, except per share amounts) 2019 2018 2019 2018 Net loss attributable to Bausch Health Companies Inc. $ (49 ) $ (350 ) $ (272 ) $ (3,804 ) Basic and diluted weighted-average common shares outstanding 352.4 351.5 351.9 351.1 Basic and diluted loss per share attributable to Bausch Health Companies Inc. $ (0.14 ) $ (1.00 ) $ (0.77 ) $ (10.83 ) During the three and nine months ended September 30, 2019 and 2018 , all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 4,453,000 and 4,238,000 common shares for the three months ended September 30, 2019 and 2018 , respectively, and approximately 4,589,000 and 3,323,000 common shares for the nine months ended September 30, 2019 and 2018 , respectively. During the three and nine months ended September 30, 2019 , time-based RSUs, performance-based RSUs and stock options to purchase approximately 5,363,000 common shares were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2018 , time-based RSUs, performance-based RSUs and stock options to purchase approximately 3,750,000 and 3,979,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS	LEGAL PROCEEDINGS From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of September 30, 2019 , the Company's Consolidated Balance Sheet includes accrued current loss contingencies of $20 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company’s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline. Governmental and Regulatory Inquiries SEC Investigation Beginning in November 2015, the Company received from the staff of the Los Angeles Regional Office of the SEC subpoenas for documents, as well as various document, testimony and interview requests, related to its investigation of the Company, including requests concerning the Company's former relationship with Philidor Rx Services, LLC ("Philidor"), its accounting practices and policies, its public disclosures and other matters. The Company is cooperating with the SEC in this matter. The Company has agreed to a tolling agreement with the SEC regarding certain potential claims. The Company cannot predict the outcome or the duration of the SEC investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of the SEC investigation. AMF Investigation On April 12, 2016, the Company received a request letter from the Autorité des marchés financiers (the “AMF”) requesting documents concerning the work of the Company’s ad hoc committee of independent directors (established to review certain allegations regarding the Company’s former relationship with Philidor and related matters), the Company’s former relationship with Philidor, the Company's accounting practices and policies and other matters. The Company is cooperating with the AMF in this matter. In July 2018, the Company was advised by the AMF that it had issued a formal investigation order against it. The Company cannot predict whether any enforcement action against the Company will result from such investigation. Investigation by the State of Texas On May 27, 2014, the State of Texas served Bausch & Lomb Incorporated ("B&L Inc.") with a Civil Investigative Demand concerning various price reporting matters relating to the State's Medicaid program and the amounts the State paid in reimbursement for B&L products for the period from 1995 to the date of the Civil Investigative Demand. The Company and B&L Inc. have cooperated fully with the State's investigation and have produced all of the documents requested by the State to date. In April 2016, the State sent B&L Inc. a demand letter claiming damages in the amount of $20 million . The Company and B&L Inc. have evaluated the letter and disagree with the allegations and methodologies set forth in the letter. In June 2016, the Company and B&L Inc. responded to the State. In August 2019, the State provided an initial response to the Company’s June 2016 letter. The matter remains pending. The Company cannot predict the duration or outcome of the matter or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of the investigation. Investigation by the U.S. Attorney's Office for the District of Massachusetts - re Arestin ® In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts. The materials requested pursuant to the subpoena include documents concerning the sales, marketing, coverage and reimbursement of Arestin ® , including related support services, and other matters. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation. Investigation by the U.S. Attorney's Office for the District of Massachusetts - re patient assistance and pricing In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, and, in June 2016, the Company received a follow-up subpoena. The materials requested, pursuant to the subpoenas and follow-up requests, include documents and witness interviews with respect to the Company’s patient assistance programs and contributions to patient assistance organizations that provide financial assistance to Medicare patients taking products sold by the Company, and the Company’s pricing of its products. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation. Investigation by the U.S. Attorney's Office for the Southern District of New York In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the Southern District of New York. The materials requested, pursuant to the subpoena and follow-up requests, include documents and witness interviews with respect to the Company’s patient assistance programs; its former relationship with Philidor and other pharmacies; the Company’s accounting treatment for sales by specialty pharmacies; information provided to the Centers for Medicare and Medicaid Services; the Company’s pricing (including discounts and rebates), marketing and distribution of its products; the Company’s compliance program; and employee compensation. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation. Securities and RICO Class Actions and Related Matters U.S. Securities Litigation In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. On May 31, 2016, the Court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 3:15-cv-07658. On June 24, 2016, the lead plaintiff filed a consolidated complaint asserting claims under Sections 10(b) and 20(a) of the Exchange Act against the Company, and certain current or former officers and directors, as well as claims under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (the “Securities Act”) against the Company, certain current or former officers and directors, and certain other parties. The lead plaintiff seeks to bring these claims on behalf of a putative class of persons who purchased the Company’s equity securities and senior notes in the United States between January 4, 2013 and March 15, 2016, including all those who purchased the Company’s securities in the United States in the Company’s debt and stock offerings between July 2013 to March 2015. On September 13, 2016, the Company and the other defendants moved to dismiss the consolidated complaint. On April 28, 2017, the Court dismissed certain claims arising out of the Company's private placement offerings and otherwise denied the motions to dismiss. On September 20, 2018, lead plaintiff filed an amended complaint, adding claims against ValueAct Capital Management L.P. and affiliated entities ("ValueAct"). On October 31, 2018, a third party defendant, ValueAct, filed a motion to dismiss. On June 30, 2019, the Court denied the motion to dismiss and ValueAct has filed for interlocutory appeal of this decision. On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 2:18-cv-10246) (“Timber Hill”), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company’s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 3:15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order. In addition to the consolidated putative class action, as previously reported in the Company’s Form 10-K, thirty-three groups of individual investors in the Company’s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions pending in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These individual shareholder actions assert claims under Sections 10(b), 18, and 20(a) of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, and negligent misrepresentation under state law, based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. Some plaintiffs additionally assert claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act and one plaintiff asserts claims under the Connecticut Uniform Securities Act. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed -and in most cases decided- in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 3:18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants’ motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (“Aly”) (Case No. 3:18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. The Company believes the individual complaints and the consolidated putative class action are without merit and intends to defend itself vigorously. Canadian Securities Litigation In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec, as previously reported in the Company's Annual Report on Form 10-K for the year ended December 31, 2018, filed on February 20, 2019. The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above. The Rosseau-Godbout action was stayed by the Quebec Superior Court by consent order. The Kowalyshyn action has been consolidated with the O’Brien action and that consolidated action is stayed in favor of the Catucci action. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings. A timetable for certain pre-trial procedural matters in the action has been set and the notice of certification has been disseminated to class members. Among other things, the timetable established a deadline of June 19, 2018 for class members to exercise their right to opt-out of the class. The Company is aware of two additional putative class actions that have been filed with the applicable court but which have not yet been served on the Company, as previously reported in the Company's Annual Report on Form 10-K for the year ended December 31, 2018, filed on February 20, 2019, and the factual allegations made in these actions are substantially similar to those outlined above. The Company has been advised that the plaintiffs in these actions do not intend to pursue the actions. In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations. The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers’ Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, California State Teachers’ Retirement System also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations. A settlement approval hearing has been scheduled for November 11, 2019 in the Quebec Superior Court of Justice to hear a motion brought by the plaintiffs in the Catucci action for approval of a settlement between the class and the Company’s auditors. The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously. Insurance Coverage Lawsuit On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493). In the lawsuit, the Company seeks coverage for (1) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (under the 2013-2014 coverage period), and (2) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and certain of the investigations described above (under the 2015-2016 coverage period). RICO Class Actions Between May 27, 2016 and September 16, 2016, three virtually identical actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties, alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (“RICO”) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company branded drugs between January 2, 2013 and November 9, 2015. On November 30, 2016, the Court entered an order consolidating the three actions under the caption In re Valeant Pharmaceuticals International, Inc. Third-Party Payor Litigation , No. 3:16-cv-03087. A consolidated class action complaint was filed on December 14, 2016. The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured’s consent to renew the prescription. The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute. The Company moved to dismiss the consolidated complaint on February 13, 2017. On March 14, 2017, other defendants filed a motion to stay the RICO class action pending the resolution of criminal proceedings against Andrew Davenport and Gary Tanner. On August 9, 2017, the Court granted the motion to stay and entered an order staying all proceedings in the case and accordingly terminating other pending motions. On April 12, 2019, the court lifted the stay. On July 30, 2019, the plaintiffs filed an amended complaint. On August 28, 2019, the Company filed a motion to dismiss the amended complaint. Briefing on this motion concluded on October 25, 2019. The Company believes these claims are without merit and intends to defend itself vigorously. Hound Partners Lawsuit On October 19, 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County. This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18). This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The factual allegations made in this complaint are similar to those made in the District of New Jersey Hound Partners action. On March 29, 2019, the Company, certain individual defendants, and Plaintiffs submitted a consent order to stay further proceedings pending the completion of discovery in the federal opt-out case Hound Partners Offshore Funds, LP et al. v. Valeant Pharmaceuticals International, Inc. (Case No. 3:18-cv-08705). On October 9, 2019, the Court entered the consent order. The Company disputes the claims and intends to vigorously defend this matter. Derivative Lawsuits On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. The cases are Wessels v. Pearson (Case No. 3:19-cv-17833) and Shabbouei v. Pearson (Case No. 3:19-cv-17987). Plaintiffs in both cases assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. The claims alleged in these cases are based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation , all of which occurred prior to 2017. The Shabbouei complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The Company disputes these claims and intends to defend itself vigorously. Antitrust Generic Pricing Antitrust Class Action As of June 2018, the Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (“Oceanside”), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (“Bausch Health US”), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (“Bausch Health Americas”) (for the purposes of this subsection, collectively, the “Company”), were added as defendants in putative class action multidistrict antitrust litigation entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation , pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16-MD-2724). The lawsuit to which the Company was added was filed by direct purchaser plaintiffs and seeks damages under federal antitrust laws, alleging that the Company’s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. Specific claims against the Company’s subsidiaries relate to generic pricing of the Company’s metronidazole vaginal product as part of an alleged overarching conspiracy among generic drug manufacturers. As of December 2018, three direct purchaser plaintiffs that had opted out of the putative class filed an amended complaint in the MDL that added Oceanside, Bausch Health US and Bausch Health Americas, alleging similar claims as the direct purchaser plaintiffs’ putative class action complaint. On October 18, 2019, Humana Inc. filed a related complaint against Oceanside, Bausch Health US and Bausch Health Americas, as well as other defendants, alleging similar claims. Separate complaints by other plaintiffs which had been consolidated in the same multidistrict litigation do not name the Company or any of its subsidiaries as a defendant. The Company has filed motions to dismiss the earlier-filed actions. On August 15, 2019, the Court denied defendants’ joint motion to dismiss claims asserting the existence of an overarching multi-drug conspiracy. The Company’s individual motion to dismiss the earlier-filed actions remains pending. Discovery against the Company’s subsidiaries has commenced. The Company continues to vigorously defend these matters. On July 18, 2019, 87 health plans filed a Praecipe to commence an action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation. As of the date hereof, Plaintiffs have not filed a Complaint. Glumetza Antitrust Class Actions In August, September and October 2019, six (6) putative antitrust class actions were filed in the Northern District of California against the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (among other defendants). Four of the cases were filed by direct purchasers and two of the cases were filed by end payer purchasers. The direct purchaser defendants seek damages under federal antitrust laws and the end payer purchasers seek damages under state antitrust, consumer protection, and unjust enrichment laws as well as injunctive relief under federal antitrust laws. The lawsuits allege that a 2012 settlement of a patent litigation regarding Glumetza ® delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza ® or grant any other company a license to do so. The complaints allege that the settlement agreement resulted in higher prices for Glumetza ® and metformin hydrochloride both prior to and after generic entry. The Company and its affiliates named in these cases dispute the claims against them and intend to vigorously defend these matters. Intellectual Property Patent Litigation/Paragraph IV Matters From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Relistor ® , Uceris ® , Xifaxan ® 200mg, Xifaxan ® 550mg, Plenvu ® , Bryhali ® , Prolensa ® and Jublia ® in the United States and Jublia ® in Canada, other similar suits. These matters are proceeding in the ordinary course. In July 2019, the Company announced that the U.S. District Court of New Jersey had upheld the validity of and determined Actavis' infringement of a patent protecting the Company's Relistor ® tablets, expiring in March 2031. In July 2019, the Company also announced that it had agreed to resolve the outstanding intellectual property litigation with Teva Pharmaceuticals USA, Inc. ("Teva") regarding Apriso ® extended-release capsules 0.375g. As part of the settlement, the parties agreed to dismiss all litigation related to Apriso ® , and intellectual property protecting Apriso ® will remain intact and enforceable. In addition, the Company will grant Teva a non-exclusive license effective October 1, 2021 to the intellectual property relating to Apriso ® in the United States (provided that Teva will be able to begin marketing prior to such date if another generic version of the product is granted approval and starts selling or distributing such generic prior to October 1, 2021). In September 2019, the Company received a Notice of Paragraph IV Certification from Sandoz, Inc. (“Sandoz”), in which Sandoz asserted that the following U.S. patents, each of which is listed in the FDA’s Orange Book for Salix Pharmaceuticals, Inc.’s (“Salix Inc.”) Xifaxan ® tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Sandoz’s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (“ANDA”) has been filed by Sandoz: U.S. Patent No. 8,309,569 (the “‘569 patent”), U.S. Patent No. 7,045,620 (the “‘620 patent”), U.S. Patent No. 7,612,199 (the “‘199 patent”), U.S. Patent No. 7,902,206 (the “‘206 patent”), U.S. Patent No. 7,906,542 (the “‘542 patent”), U.S. Patent No. 7,915,275 (the “‘275 patent”), U.S. Patent No. 8,158,644 (the “‘644 patent”), U.S. Patent No. 8,158,781 (the “‘781 patent”), U.S. Patent No. 8,193,196 (the “‘196 patent”), U.S. Patent No. 8,518,949 (the “‘949 patent”), U.S. Patent No. 8,741,904 (the “‘904 patent”), U.S. Patent No. 8,835,452 (the “‘452 patent”), U.S. Patent No. 8,853,231 (the “‘231 patent”), and U.S. Patent No. 9,271,968 (the “’968 Patent”) (collectively, the “Xifaxan ® Patents”). Salix Inc. holds the NDA for Xifaxan ® and its affiliate, Salix Pharmaceuticals, Ltd. (“Salix Ltd.”), is the owner of the ‘569 patent and Alfa Sigma S.p.A. (“Alfa Sigma”) is the owner of the ‘620 patent, the ‘199 patent, the ‘206 patent, the ‘542 patent, the ‘275 patent, the ‘644 patent, the ‘781 patent, the ‘196 patent, the ‘949 patent, the ‘904 patent, the ‘452 patent, the ‘231 patent, and the ‘968 patent, each of which has been exclusively licensed to Salix Inc. and its affiliate, Bausch Health Ireland Limited (“BIRL”) to market Xifaxan ® tablets, 550 mg. On September 30, 2019, Salix Inc. and its affiliates, Salix Ltd. and BIRL, and Alfa Sigma (the “Plaintiffs”) filed suit against Sandoz in the U.S. District Court for the District of New Jersey (Case No. 19-18566) pursuant to the Hatch-Waxman Act, alleging infringement by Sandoz of one or more claims of each of the Xifaxan ® Patents, thereby triggering a 30 -month stay of the approval of Sandoz’s ANDA for rifaximin tablets, 550 mg. Xifaxan ® is protected by 23 patents covering the composition of matter and the use of Xifaxan ® listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The claim is substantially similar to the claim brought by Actavis in February 2016 that was settled in September 2018. The Company remains confident in the strength of the Xifaxan ® patents and will continue to vigorously pursue this matter and defend its intellectual property. In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent & Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company's branded pharmaceutical products. For example, following Acrux DDS’s IPR petition, the U.S. Patent and Trial Appeal Board, in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia ® and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. Jublia ® continues to be covered by eight other Orange Book-listed patents owned by the Company, which expire in the years 2028 through 2034. Product Liability Shower to Shower ® Products Liability Litigation Since 2016, the Company has been named in one hundred and sixty-five ( 165 ) product liability lawsuits involving the Shower to Shower ® body powder product acquired in September 2012 from Johnson & Johnson; due to dismissals, only twelve ( 12 ) of such product liability suits currently remain pending, and these twelve ( 12 ) matters are subject to the Johnson & Johnson indemnification referenced below. Potential liability (including its attorneys’ fees and costs) arising out of the covered Shower to Shower ® lawsuits filed against the Company is subject to certain indemnification obligations of Johnson & Johnson owed to the Company, and legal fees and costs will be paid by Johnson & Johnson. The Company and Johnson & Johnson reached an agreement on April 17, 2019, regarding the scope of the indemnification relating to the majority of the Shower to Shower ® matters (the “Covered Matters”) and the Company has dismissed the demand for arbitration that the Company filed against Johnson & Johnson to assert its rights to indemnification. Johnson & Johnson will fully indemnify the Company in the Covered Matters, which include (i) personal injury and products liability actions arising from alleged exposure to Shower to Shower ® prior to March 2020 and (ii) consumer fraud, consumer protection

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Reportable Segments Consistent with how the Company’s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports; the Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. The following is a brief description of the Company’s segments: • The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products. • The Salix segment consists of sales in the U.S. of GI products. • The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices. • The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products. Effective in the first quarter of 2019, one product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Generics business unit in the Diversified Products segment and another product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Dentistry business unit in the Diversified Products segment as management believes the products better align with the new respective business units. These changes in product alignment are not material. Prior period presentations of business unit and segment revenues and profits have been conformed to current segment and business unit reporting structures. Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, In-process research and development costs, Restructuring and integration costs, Acquisition-related contingent consideration costs and Other income, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment. Segment Revenues and Profits Segment revenues and profits were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2019 2018 2019 2018 Revenues: Bausch + Lomb/International $ 1,175 $ 1,147 $ 3,501 $ 3,459 Salix 551 460 1,505 1,323 Ortho Dermatologics 147 176 407 457 Diversified Products 336 353 964 1,020 $ 2,209 $ 2,136 $ 6,377 $ 6,259 Segment profits: Bausch + Lomb/International $ 333 $ 341 $ 989 $ 988 Salix 375 304 995 868 Ortho Dermatologics 58 88 156 190 Diversified Products 246 267 714 766 1,012 1,000 2,854 2,812 Corporate (158 ) (167 ) (435 ) (442 ) Amortization of intangible assets (475 ) (658 ) (1,452 ) (2,142 ) Goodwill impairments — — — (2,213 ) Asset impairments (33 ) (89 ) (49 ) (434 ) Restructuring and integration costs (4 ) (3 ) (28 ) (16 ) Acquisition-related contingent consideration (3 ) 19 (2 ) 23 Other income (expense), net (10 ) 15 (15 ) 3 Operating income (loss) 329 117 873 (2,409 ) Interest income 2 3 9 9 Interest expense (406 ) (420 ) (1,221 ) (1,271 ) Loss on extinguishment of debt — — (40 ) (75 ) Foreign exchange and other 9 — 12 18 Loss before benefit from (provision for) income taxes $ (66 ) $ (300 ) $ (367 ) $ (3,728 ) Revenues by Segment and Product Category Revenues by segment and product category were as follows: Three Months Ended September 30, 2019 Three Months Ended September 30, 2018 (in millions) Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Pharmaceuticals $ 217 $ 551 $ 97 $ 207 $ 1,072 $ 222 $ 460 $ 140 $ 233 $ 1,055 Devices 375 — 46 — 421 365 — 29 — 394 OTC 371 — — — 371 352 — — — 352 Branded and Other Generics 197 — — 119 316 192 — — 115 307 Other revenues 15 — 4 10 29 16 — 7 5 28 $ 1,175 $ 551 $ 147 $ 336 $ 2,209 $ 1,147 $ 460 $ 176 $ 353 $ 2,136 Nine Months Ended September 30, 2019 Nine Months Ended September 30, 2018 (in millions) Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Pharmaceuticals $ 670 $ 1,505 $ 265 $ 617 $ 3,057 $ 667 $ 1,323 $ 346 $ 714 $ 3,050 Devices 1,127 — 130 — 1,257 1,117 — 90 — 1,207 OTC 1,063 — — — 1,063 1,046 — — — 1,046 Branded and Other Generics 582 — — 332 914 576 — — 294 870 Other revenues 59 — 12 15 86 53 — 21 12 86 $ 3,501 $ 1,505 $ 407 $ 964 $ 6,377 $ 3,459 $ 1,323 $ 457 $ 1,020 $ 6,259 The top ten products for the nine months ended September 30, 2019 and 2018 represented 38% and 36% of total revenues for the nine months ended September 30, 2019 and 2018 , respectively. Geographic Information Revenues are attributed to a geographic region based on the location of the customer and were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2019 2018 2019 2018 U.S. and Puerto Rico $ 1,369 $ 1,329 $ 3,851 $ 3,766 China 86 91 276 273 Canada 85 78 252 231 Japan 67 59 181 165 Mexico 56 56 158 153 Egypt 55 45 157 134 France 45 46 156 159 Poland 49 49 156 164 Russia 47 38 124 106 Germany 33 38 119 130 United Kingdom 27 29 85 87 Italy 18 19 62 64 Spain 18 17 62 61 Other 254 242 738 766 $ 2,209 $ 2,136 $ 6,377 $ 6,259 Major Customers Customers that accounted for 10% or more of total revenues were as follows: Nine Months Ended September 30, 2019 2018 McKesson Corporation (including McKesson Specialty) 17% 18% AmerisourceBergen Corporation 17% 18% Cardinal Health, Inc. 14% 13%

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation and Use of Estimates The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S. GAAP that are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 , filed with the U.S. Securities and Exchange Commission (the “SEC”) and the Canadian Securities Administrators on February 20, 2019. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited Consolidated Financial Statements for the year ended December 31, 2018 , except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.
Use of Estimates	In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.
Principles of Consolidation	Principles of Consolidation The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.
Adoption of New Accounting Guidance and Recently Issued Accounting Standards, Not Adopted as of September 30, 2019	Adoption of New Accounting Guidance In February 2016, the Financial Accounting Standards Board ("FASB") issued a new standard revising the accounting for leases to increase transparency and comparability among organizations that lease buildings, equipment and other assets by requiring the recognition of lease assets and lease liabilities on the balance sheet. Under the new standard, all leases are classified as either a finance lease or an operating lease. The classification is determined based on whether substantive control has been transferred to the lessee and its determination will govern the pattern of lease cost recognition. Finance leases are accounted for in substantially the same manner as capital leases under the former U.S. GAAP standard. Operating leases are accounted for in the statements of operations and statements of cash flows in a manner substantially consistent with operating leases under the former U.S. GAAP standard. However, as it relates to the balance sheet, operating lessees are, with limited exception, required to record a right-of-use asset and a corresponding lease liability, equal to the present value of the lease payments for each operating lease. Lessees are not required to recognize a right-of-use asset or lease liability for short-term leases, but instead recognizes lease payments as an expense on a straight-line basis over the lease term. The standard also requires lessees and lessors to provide additional qualitative and quantitative disclosures to help financial statement users assess the amounts, timing and uncertainty of cash flows arising from leases. The Company adopted the new standard effective January 1, 2019, using the modified retrospective approach. Upon adoption, the Company elected the available practical expedients, including: (i) the package of practical expedients as defined in the accounting guidance, which among other things, allowed the carry forward of historical lease classifications, (ii) the election to use hindsight in determining the lease terms for all leases, (iii) the transition method, which does not require the restatement of prior periods, (iv) the election to aggregate lease components with non-lease components and account for these payments as a single lease component and (v) the short-term lease exemption, which does not require recognition on the balance sheet for leases with an initial term of 12 months or less. The Company has updated its systems, processes and controls to track, record and account for its lease portfolio, including implementation of a third-party software tool to assist in complying with the new standard. Upon adoption of the new standard, the Company recognized a right-of-use asset and a corresponding lease liability of $302 million . In addition, approximately $20 million of restructuring liabilities associated with facility closures and deferred rents, included in Other non-current liabilities as of December 31, 2018, were reclassified to reduce right-of-use assets. The adoption of the standard did not have a material impact on the Consolidated Statements of Operations, Comprehensive Loss, Equity and Cash Flows for any of the periods presented. See Note 12, "LEASES" for additional details and application of this standard. In August 2018, the FASB issued guidance aligning the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company has early-adopted this guidance prospectively for all implementation costs incurred after January 1, 2019. Recently Issued Accounting Standards, Not Adopted as of September 30, 2019 In June 2016, the FASB issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods within those annual periods. In May 2019, the FASB issued an update allowing a targeted transition relief for the option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. The Company is evaluating the impact of adoption of this guidance on its financial position, results of operations and cash flows. In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement. The guidance is effective for annual periods beginning after December 15, 2019. The Company is permitted to early-adopt any removed or modified disclosures upon issuance of this update and delay adoption of the additional disclosures until the effective date. The Company is evaluating the impact of adoption of this guidance on its disclosures. In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted. The Company is evaluating the impact of adoption of this guidance on its disclosures.
Revenue Recognition	REVENUE RECOGNITION The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 20, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. Product Sales Provisions As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Summary of variable consideration provisions	The following tables present the activity and ending balances of the Company’s variable consideration provisions for the nine months ended September 30, 2019 and 2018 . Nine Months Ended September 30, 2019 (in millions) Discounts and Allowances Returns Rebates Chargebacks Distribution Fees Total Reserve balances, January 1, 2019 $ 175 $ 813 $ 1,024 $ 209 $ 163 $ 2,384 Acquisition of Synergy — 3 12 — 1 16 Current period provisions 585 50 1,650 1,425 150 3,860 Payments and credits (583 ) (187 ) (1,673 ) (1,480 ) (181 ) (4,104 ) Reserve balances, September 30, 2019 $ 177 $ 679 $ 1,013 $ 154 $ 133 $ 2,156 Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $26 million and $26 million as of September 30, 2019 and January 1, 2019, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits for the nine months ended September 30, 2019 . Nine Months Ended September 30, 2018 (in millions) Discounts and Allowances Returns Rebates Chargebacks Distribution Fees Total Reserve balances, January 1, 2018 $ 167 $ 863 $ 1,094 $ 274 $ 148 $ 2,546 Current period provisions 643 209 1,976 1,462 178 4,468 Payments and credits (632 ) (264 ) (1,939 ) (1,512 ) (167 ) (4,514 ) Reserve balances, September 30, 2018 $ 178 $ 808 $ 1,131 $ 224 $ 159 $ 2,500

ACQUISITION AND ASSETS HELD F_2

ACQUISITION AND ASSETS HELD FOR SALE (Tables)	9 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Estimated fair values of assets acquired and liabilities assumed	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date: (in millions) Accounts receivable $ 7 Inventories 24 Prepaid expenses and other current assets 5 Product brand intangible assets (estimated useful life - 7 years) 159 Accounts payable (1 ) Accrued expenses (17 ) Total identifiable net assets 177 Goodwill 3 Total fair value of consideration transferred $ 180

FAIR VALUE MEASUREMENTS AND F_2

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of components and classification of financial assets and liabilities measured at fair value	The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis: September 30, 2019 December 31, 2018 (in millions) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 284 $ 250 $ 34 $ — $ 197 $ 166 $ 31 $ — Restricted cash $ 2 $ 2 $ — $ — $ 2 $ 2 $ — $ — Cross-currency swaps $ 8 $ — $ 8 $ — $ — $ — $ — $ — Liabilities: Acquisition-related contingent consideration $ 313 $ — $ — $ 313 $ 339 $ — $ — $ 339
Schedule of effect of hedging instruments on financial statements	The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations: Gain recognized in Other Comprehensive Loss Gain excluded from assessment of hedge effectiveness Location of gain in income of excluded component (in millions) Three Months Ended Nine Months Ended Three Months Ended Nine Months Ended Cross-currency swaps $ 5 $ 5 $ 3 $ 3 Interest expense
Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)	The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the nine months ended September 30, 2019 and 2018 : (in millions) 2019 2018 Balance, beginning of period $ 339 $ 387 Adjustments to Acquisition-related contingent consideration: Accretion for the time value of money $ 16 $ 18 Fair value adjustments due to changes in estimates of other future payments (14 ) (41 ) Acquisition-related contingent consideration 2 (23 ) Payments (28 ) (28 ) Balance, end of period 313 336 Current portion included in Accrued and other current liabilities 46 54 Non-current portion $ 267 $ 282
Schedule of assets and liabilities measured at fair value on a non-recurring basis	The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis: September 30, 2019 December 31, 2018 (in millions) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Other non-current assets: Non-current assets held for sale $ 39 $ — $ — $ 39 $ — $ — $ — $ —

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Schedule of the components of inventories	Inventories, net of allowances for obsolescence consist of: (in millions) September 30, December 31, Raw materials $ 317 $ 275 Work in process 171 95 Finished goods 612 564 $ 1,100 $ 934

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of indefinite-lived intangible assets	The major components of intangible assets consist of: September 30, 2019 December 31, 2018 (in millions) Gross Carrying Amount Accumulated Amortization and Impairments Net Carrying Amount Gross Carrying Amount Accumulated Amortization and Impairments Net Carrying Amount Finite-lived intangible assets: Product brands $ 20,963 $ (13,125 ) $ 7,838 $ 20,891 $ (11,958 ) $ 8,933 Corporate brands 925 (317 ) 608 926 (263 ) 663 Product rights/patents 3,292 (2,828 ) 464 3,292 (2,658 ) 634 Partner relationships 159 (157 ) 2 168 (166 ) 2 Technology and other 206 (183 ) 23 208 (173 ) 35 Total finite-lived intangible assets 25,545 (16,610 ) 8,935 25,485 (15,218 ) 10,267 Acquired IPR&D not in service 17 — 17 36 — 36 Bausch + Lomb Trademark 1,698 — 1,698 1,698 — 1,698 $ 27,260 $ (16,610 ) $ 10,650 $ 27,219 $ (15,218 ) $ 12,001
Schedule of finite-lived intangible assets	The major components of intangible assets consist of: September 30, 2019 December 31, 2018 (in millions) Gross Carrying Amount Accumulated Amortization and Impairments Net Carrying Amount Gross Carrying Amount Accumulated Amortization and Impairments Net Carrying Amount Finite-lived intangible assets: Product brands $ 20,963 $ (13,125 ) $ 7,838 $ 20,891 $ (11,958 ) $ 8,933 Corporate brands 925 (317 ) 608 926 (263 ) 663 Product rights/patents 3,292 (2,828 ) 464 3,292 (2,658 ) 634 Partner relationships 159 (157 ) 2 168 (166 ) 2 Technology and other 206 (183 ) 23 208 (173 ) 35 Total finite-lived intangible assets 25,545 (16,610 ) 8,935 25,485 (15,218 ) 10,267 Acquired IPR&D not in service 17 — 17 36 — 36 Bausch + Lomb Trademark 1,698 — 1,698 1,698 — 1,698 $ 27,260 $ (16,610 ) $ 10,650 $ 27,219 $ (15,218 ) $ 12,001
Schedule of estimated aggregate amortization expense for each of the five succeeding years	Estimated amortization expense of finite-lived intangible assets for the remainder of 2019 and each of the five succeeding years ending December 31 and thereafter is as follows: (in millions) Remainder of 2019 2020 2021 2022 2023 2024 Thereafter Total Amortization $ 444 $ 1,623 $ 1,374 $ 1,224 $ 1,080 $ 952 $ 2,238 $ 8,935
Schedule of changes in the carrying amount of goodwill	The changes in the carrying amounts of goodwill during the nine months ended September 30, 2019 and the year ended December 31, 2018 were as follows: (in millions) Bausch + Lomb/ International Branded Rx U.S. Diversified Products Salix Ortho Dermatologics Diversified Products Total Balance, January 1, 2018 $ 6,016 $ 6,631 $ 2,946 $ — $ — $ — $ 15,593 Impairment of the Salix and Ortho Dermatologics reporting units — (2,213 ) — — — — (2,213 ) Realignment of Global Solta reporting unit goodwill (82 ) 115 (33 ) — — — — Goodwill reclassified to assets held for sale and subsequently disposed (2 ) — — — — — (2 ) Realignment of segment goodwill — (4,533 ) (2,913 ) 3,156 1,267 3,023 — Impairment of the Dentistry reporting unit — — — — — (109 ) (109 ) Foreign exchange and other (127 ) — — — — — (127 ) Balance, December 31, 2018 5,805 — — 3,156 1,267 2,914 13,142 Acquisition of certain assets of Synergy — — — 3 — — 3 Goodwill reclassified to assets held for sale (Note 4) (18 ) — — — — — (18 ) Foreign exchange and other (75 ) — — — — — (75 ) Balance, September 30, 2019 $ 5,712 $ — $ — $ 3,159 $ 1,267 $ 2,914 $ 13,052

ACCRUED AND OTHER CURRENT LIA_2

ACCRUED AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Schedule of accrued and other current liabilities	Accrued and other current liabilities consist of: (in millions) September 30, December 31, 2018 Product rebates $ 987 $ 998 Product returns 679 813 Interest 388 273 Employee compensation and benefit costs 291 301 Income taxes payable 150 167 Other 703 645 $ 3,198 $ 3,197

FINANCING ARRANGEMENTS (Tables)

FINANCING ARRANGEMENTS (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of long-term debt	Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: September 30, 2019 December 31, 2018 (in millions) Maturity Principal Amount Net of Premiums, Discounts and Issuance Costs Principal Amount Net of Premiums, Discounts and Issuance Costs Senior Secured Credit Facilities: 2023 Revolving Credit Facility June 2023 $ — $ — $ 75 $ 75 June 2025 Term Loan B Facility June 2025 3,932 3,826 4,394 4,269 November 2025 Term Loan B Facility November 2025 1,312 1,293 1,481 1,456 Senior Secured Notes: 6.50% Secured Notes March 2022 1,250 1,241 1,250 1,239 7.00% Secured Notes March 2024 2,000 1,982 2,000 1,979 5.50% Secured Notes November 2025 1,750 1,732 1,750 1,730 5.75% Secured Notes August 2027 500 493 — — Senior Unsecured Notes: 5.625% December 2021 — — 700 697 5.50% March 2023 402 400 1,000 995 5.875% May 2023 1,548 1,540 3,250 3,229 4.50% euro-denominated debt May 2023 1,635 1,626 1,720 1,709 6.125% April 2025 3,250 3,229 3,250 3,226 9.00% December 2025 1,500 1,472 1,500 1,469 9.25% April 2026 1,500 1,484 1,500 1,482 8.50% January 2027 1,750 1,756 750 738 7.00% January 2028 750 740 — — 7.25% May 2029 750 740 — — Other Various 12 12 12 12 Total long-term debt and other $ 23,841 23,566 $ 24,632 24,305 Less: Current portion of long-term debt and other 100 228 Non-current portion of long-term debt $ 23,466 $ 24,077
Schedule of long-term debt maturities	Maturities and mandatory payments of debt obligations for the remainder of 2019 , the five succeeding years ending December 31 and thereafter are as follows: (in millions) Remainder of 2019 $ 100 2020 — 2021 203 2022 1,553 2023 3,788 2024 2,303 Thereafter 15,894 Total debt obligations 23,841 Unamortized premiums, discounts and issuance costs (275 ) Total long-term debt and other $ 23,566

PENSION AND POSTRETIREMENT EM_2

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)	9 Months Ended
	Sep. 30, 2019
Retirement Benefits [Abstract]
Components of net periodic benefit cost	Net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2019 and 2018 consists of: Pension Benefit Plans Postretirement U.S. Plan Non-U.S. Plans (in millions) 2019 2018 2019 2018 2019 2018 Service cost $ 1 $ 1 $ 2 $ 2 $ — $ — Interest cost 6 5 4 4 1 1 Expected return on plan assets (10 ) (11 ) (4 ) (4 ) — — Amortization of prior service credit — — (1 ) (1 ) (2 ) (2 ) Amortization of net loss — — 1 1 — — Net periodic (benefit) cost $ (3 ) $ (5 ) $ 2 $ 2 $ (1 ) $ (1 )

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Summary of right-of-use assets and right-of-use liabilities	Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of September 30, 2019 as follows: (in millions) Right-of-use assets included in: Other non-current assets $ 263 Lease liabilities included in: Accrued and other current liabilities $ 49 Other non-current liabilities 235 Total lease liabilities $ 284
Summary of lease expenses	Lease expense includes: (in millions) Three Months Ended Nine Months Ended Operating lease costs $ 15 $ 47 Variable operating lease costs $ 3 $ 12 Short-term lease expense $ 1 $ 2
Summary of other operating lease information	Other information related to operating leases for the nine months ended September 30, 2019 is as follows: (dollars in millions) Cash paid from operating cash flows for amounts included in the measurement of lease liabilities $ 56 Right-of-use assets obtained in exchange for new operating lease liabilities $ 28 Weighted-average remaining lease term 8.5 years Weighted-average discount rate 6.2 %
Summary of operating lease future payments, after adoption of 842	As of September 30, 2019 , future payments under noncancelable operating leases for the remainder of 2019, each of the five succeeding years ending December 31 and thereafter are as follows: (in millions) Remainder of 2019 $ 16 2020 63 2021 49 2022 39 2023 34 2024 28 Thereafter 146 Total 375 Less: Imputed interest 91 Present value of remaining lease payments 284 Less: Current portion 49 Non-current portion $ 235
Summary of operating lease future payments, before adoption of 842	Accordingly, the Company is providing the following table of future payments under noncancelable operating leases as of December 31, 2018, for each of the five succeeding years ending December 31 and thereafter as previously disclosed under prior accounting guidance: (in millions) 2019 2020 2021 2022 2023 Thereafter Total Future payments $ 78 $ 60 $ 44 $ 39 $ 32 $ 166 $ 419

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Summary of the components and classification of share-based compensation expense	The following table summarizes the components and classification of share-based compensation expense related to stock options and RSUs for the three and nine months ended September 30, 2019 and 2018 : Three Months Ended Nine Months Ended (in millions) 2019 2018 2019 2018 Stock options $ 5 $ 6 $ 17 $ 17 RSUs 21 16 60 48 $ 26 $ 22 $ 77 $ 65 Research and development expenses $ 2 $ 3 $ 7 $ 7 Selling, general and administrative expenses 24 19 70 58 $ 26 $ 22 $ 77 $ 65
Summary of share-based awards	Share-based awards granted consist of: Nine Months Ended September 30, 2019 2018 Stock options Granted 1,725,000 2,106,000 Weighted-average exercise price $ 23.16 $ 15.46 Weighted-average grant date fair value $ 8.46 $ 7.82 Time-based RSUs Granted 2,895,000 2,844,000 Weighted-average grant date fair value $ 23.93 $ 17.36 TSR performance-based RSUs Granted 454,000 469,000 Weighted-average grant date fair value $ 34.53 $ 29.35 ROTC performance-based RSUs Granted 505,000 409,000 Weighted-average grant date fair value $ 25.03 $ 18.80

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	9 Months Ended
	Sep. 30, 2019
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Schedule of the components of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consists of: (in millions) September 30, December 31, Foreign currency translation adjustments $ (2,129 ) $ (2,111 ) Pension and postretirement benefit plan adjustments, net of tax (27 ) (26 ) $ (2,156 ) $ (2,137 )

RESEARCH AND DEVELOPMENT (Table

RESEARCH AND DEVELOPMENT (Tables)	9 Months Ended
	Sep. 30, 2019
Research and Development [Abstract]
Summary of research and development	Research and development costs consist of: Three Months Ended Nine Months Ended (in millions) 2019 2018 2019 2018 Product related research and development $ 114 $ 98 $ 329 $ 265 Quality assurance 9 9 28 28 $ 123 $ 107 $ 357 $ 293

OTHER EXPENSE (INCOME), NET (Ta

OTHER EXPENSE (INCOME), NET (Tables)	9 Months Ended
	Sep. 30, 2019
Other Income and Expenses [Abstract]
Schedule of other expense (income), net	Other expense (income), net consists of: Three Months Ended Nine Months Ended (in millions) 2019 2018 2019 2018 Net (gain) loss on sale of assets $ (1 ) $ 26 $ (10 ) $ 26 Acquisition-related costs — — 8 1 Litigation and other matters 9 (40 ) 12 (30 ) Other, net 2 (1 ) 5 — $ 10 $ (15 ) $ 15 $ (3 )

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule of calculation of earnings per share	Loss per share attributable to Bausch Health Companies Inc. were calculated as follows: Three Months Ended Nine Months Ended (in millions, except per share amounts) 2019 2018 2019 2018 Net loss attributable to Bausch Health Companies Inc. $ (49 ) $ (350 ) $ (272 ) $ (3,804 ) Basic and diluted weighted-average common shares outstanding 352.4 351.5 351.9 351.1 Basic and diluted loss per share attributable to Bausch Health Companies Inc. $ (0.14 ) $ (1.00 ) $ (0.77 ) $ (10.83 )

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Schedule of segment revenues and profit	Segment revenues and profits were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2019 2018 2019 2018 Revenues: Bausch + Lomb/International $ 1,175 $ 1,147 $ 3,501 $ 3,459 Salix 551 460 1,505 1,323 Ortho Dermatologics 147 176 407 457 Diversified Products 336 353 964 1,020 $ 2,209 $ 2,136 $ 6,377 $ 6,259 Segment profits: Bausch + Lomb/International $ 333 $ 341 $ 989 $ 988 Salix 375 304 995 868 Ortho Dermatologics 58 88 156 190 Diversified Products 246 267 714 766 1,012 1,000 2,854 2,812 Corporate (158 ) (167 ) (435 ) (442 ) Amortization of intangible assets (475 ) (658 ) (1,452 ) (2,142 ) Goodwill impairments — — — (2,213 ) Asset impairments (33 ) (89 ) (49 ) (434 ) Restructuring and integration costs (4 ) (3 ) (28 ) (16 ) Acquisition-related contingent consideration (3 ) 19 (2 ) 23 Other income (expense), net (10 ) 15 (15 ) 3 Operating income (loss) 329 117 873 (2,409 ) Interest income 2 3 9 9 Interest expense (406 ) (420 ) (1,221 ) (1,271 ) Loss on extinguishment of debt — — (40 ) (75 ) Foreign exchange and other 9 — 12 18 Loss before benefit from (provision for) income taxes $ (66 ) $ (300 ) $ (367 ) $ (3,728 )
Schedule of revenues by segment and product category	Revenues by segment and product category were as follows: Three Months Ended September 30, 2019 Three Months Ended September 30, 2018 (in millions) Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Pharmaceuticals $ 217 $ 551 $ 97 $ 207 $ 1,072 $ 222 $ 460 $ 140 $ 233 $ 1,055 Devices 375 — 46 — 421 365 — 29 — 394 OTC 371 — — — 371 352 — — — 352 Branded and Other Generics 197 — — 119 316 192 — — 115 307 Other revenues 15 — 4 10 29 16 — 7 5 28 $ 1,175 $ 551 $ 147 $ 336 $ 2,209 $ 1,147 $ 460 $ 176 $ 353 $ 2,136 Nine Months Ended September 30, 2019 Nine Months Ended September 30, 2018 (in millions) Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Bausch + Lomb/ International Salix Ortho Dermatologics Diversified Products Total Pharmaceuticals $ 670 $ 1,505 $ 265 $ 617 $ 3,057 $ 667 $ 1,323 $ 346 $ 714 $ 3,050 Devices 1,127 — 130 — 1,257 1,117 — 90 — 1,207 OTC 1,063 — — — 1,063 1,046 — — — 1,046 Branded and Other Generics 582 — — 332 914 576 — — 294 870 Other revenues 59 — 12 15 86 53 — 21 12 86 $ 3,501 $ 1,505 $ 407 $ 964 $ 6,377 $ 3,459 $ 1,323 $ 457 $ 1,020 $ 6,259
Schedule of revenue attributed to a geographic region	Revenues are attributed to a geographic region based on the location of the customer and were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2019 2018 2019 2018 U.S. and Puerto Rico $ 1,369 $ 1,329 $ 3,851 $ 3,766 China 86 91 276 273 Canada 85 78 252 231 Japan 67 59 181 165 Mexico 56 56 158 153 Egypt 55 45 157 134 France 45 46 156 159 Poland 49 49 156 164 Russia 47 38 124 106 Germany 33 38 119 130 United Kingdom 27 29 85 87 Italy 18 19 62 64 Spain 18 17 62 61 Other 254 242 738 766 $ 2,209 $ 2,136 $ 6,377 $ 6,259
Schedule of customers that accounted for 10% or more of total revenue	Customers that accounted for 10% or more of total revenues were as follows: Nine Months Ended September 30, 2019 2018 McKesson Corporation (including McKesson Specialty) 17% 18% AmerisourceBergen Corporation 17% 18% Cardinal Health, Inc. 14% 13%

DESCRIPTION OF BUSINESS - Narra

DESCRIPTION OF BUSINESS - Narrative (Details)	Sep. 30, 2019country
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of countries in which entity operates	100

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use asset	$ 263	$ 302
Lease liability	284	302
Other non-current liabilities adjustment, upon adoption of ASU	(760)		$ (581)
Reduction, right-of-use asset, upon adoption of ASU	$ (263)	(302)
Restatement Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use asset		(20)
Other non-current liabilities adjustment, upon adoption of ASU		20
Reduction, right-of-use asset, upon adoption of ASU		$ 20

REVENUE RECOGNITION - Narrative

REVENUE RECOGNITION - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cooperative advertising credits included in rebates	$ 2,156,000,000	$ 2,500,000,000	$ 2,156,000,000	$ 2,500,000,000		$ 2,384,000,000	$ 2,546,000,000
Price appreciation credits	2,209,000,000	2,136,000,000	6,377,000,000	6,259,000,000
Price Appreciation Credit
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Price appreciation credits			0	15,000,000
Sales Returns
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net improvement in provision			159,000,000
Reduction in variable consideration provision, adjustment	80,000,000	30,000,000
Cooperative advertising credits included in rebates	679,000,000	808,000,000	679,000,000	808,000,000		$ 813,000,000	$ 863,000,000
Rebates, Advertising Credits Portion
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cooperative advertising credits included in rebates	$ 26,000,000	$ 29,000,000	$ 26,000,000	$ 29,000,000	$ 26,000,000

REVENUE RECOGNITION - Variable

REVENUE RECOGNITION - Variable Consideration Provisions (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Reserve beginning balance	$ 2,384	$ 2,546
Acquisition of Synergy	16
Current period provisions	3,860	4,468
Payments and credits	(4,104)	(4,514)
Reserve ending balance	2,156	2,500
Discounts and Allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Reserve beginning balance	175	167
Acquisition of Synergy	0
Current period provisions	585	643
Payments and credits	(583)	(632)
Reserve ending balance	177	178
Returns
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Reserve beginning balance	813	863
Acquisition of Synergy	3
Current period provisions	50	209
Payments and credits	(187)	(264)
Reserve ending balance	679	808
Rebates
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Reserve beginning balance	1,024	1,094
Acquisition of Synergy	12
Current period provisions	1,650	1,976
Payments and credits	(1,673)	(1,939)
Reserve ending balance	1,013	1,131
Chargebacks
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Reserve beginning balance	209	274
Acquisition of Synergy	0
Current period provisions	1,425	1,462
Payments and credits	(1,480)	(1,512)
Reserve ending balance	154	224
Distribution Fees
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Reserve beginning balance	163	148
Acquisition of Synergy	1
Current period provisions	150	178
Payments and credits	(181)	(167)
Reserve ending balance	$ 133	$ 159

ACQUISITION AND ASSETS HELD F_3

ACQUISITION AND ASSETS HELD FOR SALE - Narrative (Details) - USD ($) $ in Millions	Mar. 06, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Business Acquisition [Line Items]
Advisory, legal, valuation, accounting and other similar services, included in other (income) expense		$ 10	$ (15)		$ 15	$ (3)
Disposal Group, Held-for-sale, Not Discontinued Operations
Business Acquisition [Line Items]
Impairment of long-lived assets classified as held for sale					8	5
Disposal Group, Held-for-sale, Not Discontinued Operations | Certain Products For Disposal, September 2019
Business Acquisition [Line Items]
Revenue associated with products for disposal					11		$ 19
Impairment of long-lived assets classified as held for sale		$ 8			8
Synergy Pharmaceuticals Inc.
Business Acquisition [Line Items]
Cash payments to acquire certain assets and assumed liabilities	$ 180
Revenue of acquiree since acquisition date				$ 37
Operating results of acquiree since acquisition				$ 0
Pro forma revenue					0	0
Pro forma operating results					0	$ 0
Advisory, legal, valuation, accounting and other similar services, included in other (income) expense					$ 8

ACQUISITION AND ASSETS HELD F_4

ACQUISITION AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Mar. 06, 2019	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill		$ 13,052	$ 13,142	$ 15,593
Synergy Pharmaceuticals Inc.
Business Acquisition [Line Items]
Accounts receivable	$ 7
Inventories	24
Prepaid expenses and other current assets	5
Product brand intangible assets (estimated useful life - 7 years)	159
Accounts payable	(1)
Accrued expenses	(17)
Total identifiable net assets	177
Goodwill	3
Total fair value of consideration transferred	$ 180
Product brand intangible assets, useful life	7 years

RESTRUCTURING AND INTEGRATION_2

RESTRUCTURING AND INTEGRATION COSTS - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Acquisition-Related Restructuring Costs
Cost-rationalization and integration initiatives
Remaining restructuring liabilities	$ 28
Other Restructuring, Integration-related and Other Costs
Cost-rationalization and integration initiatives
Incurred restructuring costs	28	$ 16
Severance costs	8	8
Business exit costs	9	8
Restructuring payments	27	$ 29
Other Restructuring, Integration-related and Other Costs | Synergy Pharmaceuticals Inc.
Cost-rationalization and integration initiatives
Severance costs	$ 11

FAIR VALUE MEASUREMENTS AND F_3

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Liabilities:
Highly liquid investments, maturity period (in months) (or less)	3 months
Recurring basis
Assets:
Cash equivalents	$ 284	$ 197
Restricted cash	2	2
Liabilities:
Acquisition-related contingent consideration	313	339
Recurring basis | Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument
Assets:
Cross-currency swaps	8	0
Recurring basis | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Cash equivalents	250	166
Restricted cash	2	2
Liabilities:
Acquisition-related contingent consideration	0	0
Recurring basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument
Assets:
Cross-currency swaps	0	0
Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Cash equivalents	34	31
Restricted cash	0	0
Liabilities:
Acquisition-related contingent consideration	0	0
Recurring basis | Significant Other Observable Inputs (Level 2) | Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument
Assets:
Cross-currency swaps	8	0
Recurring basis | Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	0	0
Restricted cash	0	0
Liabilities:
Acquisition-related contingent consideration	313	339
Recurring basis | Significant Unobservable Inputs (Level 3) | Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument
Assets:
Cross-currency swaps	$ 0	$ 0

FAIR VALUE MEASUREMENTS AND F_4

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments or receipts in settlement of cross-currency swaps	$ 0
Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate notional amounts	1,250,000,000
Fair value cross-currency swaps asset	$ 8,000,000

FAIR VALUE MEASUREMENTS AND F_5

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - Net Investment Hedging - Cross-currency swaps - Designated as Hedging Instrument - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Gain recognized in Other Comprehensive Loss	$ 5	$ 5
Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain excluded from assessment of hedge effectiveness	$ 3	$ 3

FAIR VALUE MEASUREMENTS AND F_6

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Included in fair value adjustments due to changes in estimates of other future payments	$ 2	$ (23)
Fair Value Adjustments, Changes In Estimates Of Other Future Payments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Included in fair value adjustments due to changes in estimates of other future payments	(14)	$ (41)
Fair Value Adjustments, Changes In Estimates Of Other Future Payments | 2011 Acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Included in fair value adjustments due to changes in estimates of other future payments	$ 8
Recurring basis | Measurement Input, Discount Rate | Significant Unobservable Inputs (Level 3) | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, contingent consideration obligations, discount rate	0.05
Recurring basis | Measurement Input, Discount Rate | Significant Unobservable Inputs (Level 3) | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, contingent consideration obligations, discount rate	0.25

FAIR VALUE MEASUREMENTS AND F_7

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Balance at the beginning of the period	$ 339	$ 387
Acquisition-related contingent consideration	2	(23)
Payments	(28)	(28)
Balance at the end of the period	313	336
Current portion included in Accrued and other current liabilities	46	54
Non-current portion	267	282
Accretion for the time value of money
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Acquisition-related contingent consideration	16	18
Fair value adjustments due to changes in estimates of other future payments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Acquisition-related contingent consideration	$ (14)	$ (41)

FAIR VALUE MEASUREMENTS AND F_8

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details) - Fair Value, Nonrecurring - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Other non-current assets:
Non-current assets held for sale	$ 39	$ 0
Quoted Prices in Active Markets for Identical Assets (Level 1)
Other non-current assets:
Non-current assets held for sale	0	0
Significant Other Observable Inputs (Level 2)
Other non-current assets:
Non-current assets held for sale	0	0
Significant Unobservable Inputs (Level 3)
Other non-current assets:
Non-current assets held for sale	$ 39	$ 0

FAIR VALUE MEASUREMENTS AND F_9

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Assets Measured at Fair Value on a Recurring Basis
Asset impairments	$ 33	$ 89	$ 49	$ 434
Disposal Group, Held-for-sale, Not Discontinued Operations
Assets Measured at Fair Value on a Recurring Basis
Impairment of long-lived assets classified as held for sale			8	$ 5
Certain Products For Disposal, September 2019 | Disposal Group, Held-for-sale, Not Discontinued Operations
Assets Measured at Fair Value on a Recurring Basis
Impairment of long-lived assets classified as held for sale	8		8
Nonrecurring adjustment
Assets Measured at Fair Value on a Recurring Basis
Non-current assets held for sale	39		39		$ 0
Nonrecurring adjustment | Significant Other Observable Inputs (Level 2)
Assets Measured at Fair Value on a Recurring Basis
Non-current assets held for sale	0		0		0
Fair value of long-term debt	$ 25,005		$ 25,005		$ 23,357

INVENTORIES - Components of Inv

INVENTORIES - Components of Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 317	$ 275
Work in process	171	95
Finished goods	612	564
Total Inventories	$ 1,100	$ 934

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Finite-lived intangible assets:
Gross Carrying Amount	$ 25,545	$ 25,485
Accumulated Amortization and Impairments	(16,610)	(15,218)
Net Carrying Amount	8,935	10,267
Total intangible assets
Gross Carrying Amount	27,260	27,219
Net Carrying Amount	10,650	12,001
Acquired IPR&D not in service
Indefinite-lived intangible assets:
Net Carrying Amount	17	36
Bausch Lomb Trademark
Indefinite-lived intangible assets:
Net Carrying Amount	1,698	1,698
Product brands
Finite-lived intangible assets:
Gross Carrying Amount	20,963	20,891
Accumulated Amortization and Impairments	(13,125)	(11,958)
Net Carrying Amount	7,838	8,933
Bausch Lomb Trademark
Finite-lived intangible assets:
Gross Carrying Amount	925	926
Accumulated Amortization and Impairments	(317)	(263)
Net Carrying Amount	608	663
Product rights/patents
Finite-lived intangible assets:
Gross Carrying Amount	3,292	3,292
Accumulated Amortization and Impairments	(2,828)	(2,658)
Net Carrying Amount	464	634
Partner relationships
Finite-lived intangible assets:
Gross Carrying Amount	159	168
Accumulated Amortization and Impairments	(157)	(166)
Net Carrying Amount	2	2
Technology and other
Finite-lived intangible assets:
Gross Carrying Amount	206	208
Accumulated Amortization and Impairments	(183)	(173)
Net Carrying Amount	$ 23	$ 35

INTANGIBLE ASSETS AND GOODWIL_3

INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)	Oct. 01, 2018	Jan. 01, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Mar. 31, 2018	Mar. 01, 2018	Dec. 31, 2017
Goodwill [Line Items]
Impairment of intangible assets						$ 38,000,000	$ 341,000,000
Net carrying amount			$ 10,650,000,000			10,650,000,000		$ 12,001,000,000
Decrease to net loss attributable to Bausch Health Companies Inc.			$ (49,000,000)	$ (350,000,000)		$ (272,000,000)	$ (3,804,000,000)
Decrease to earnings per share, basic and diluted (in usd per share)			$ (0.14)	$ (1)		$ (0.77)	$ (10.83)
Goodwill impairment			$ 0	$ 0		$ 0	$ 2,213,000,000
Goodwill reallocated into (out of)			13,052,000,000			13,052,000,000		13,142,000,000			$ 15,593,000,000
Accumulated goodwill impairment charges			3,711,000,000			3,711,000,000
Ortho Dermatologics
Goodwill [Line Items]
Goodwill impairment								2,213,000,000
Dentistry Reporting Unit
Goodwill [Line Items]
Goodwill impairment	$ 109,000,000							$ 109,000,000
Reporting Units Excluding Dentistry
Goodwill [Line Items]
Goodwill impairment	$ 0
Branded Rx | Adjustments
Goodwill [Line Items]
Goodwill reallocated into (out of)										$ 115,000,000
Branded Rx | Salix
Goodwill [Line Items]
Goodwill impairment		$ 1,970,000,000
Branded Rx | Ortho Dermatologics
Goodwill [Line Items]
Goodwill impairment		$ 243,000,000
Bausch Lomb/International and U.S. Diversified Products Segments | Adjustments
Goodwill [Line Items]
Goodwill reallocated into (out of)									$ (115,000,000)
Minimum
Goodwill [Line Items]
Reporting unit, impairment test, long-term growth rate	1.00%
Reporting unit, impairment test, estimated cash flows, discount rate	7.50%
Maximum
Goodwill [Line Items]
Reporting unit, impairment test, long-term growth rate	3.00%
Reporting unit, impairment test, estimated cash flows, discount rate	14.00%
Uceris
Goodwill [Line Items]
Impairment of intangible assets					$ 263,000,000
Net carrying amount			70,000,000			70,000,000
Xifaxan
Goodwill [Line Items]
Net carrying amount			$ 4,444,000,000			4,444,000,000
Xifaxan | Intangible Assets, Amortization Period
Goodwill [Line Items]
Decrease to net loss attributable to Bausch Health Companies Inc.						$ 353,000,000
Decrease to earnings per share, basic and diluted (in usd per share)						$ 1
Acquired IPR&D not in service
Goodwill [Line Items]
Impairment of indefinite-lived intangible assets							28,000,000
Held-for-sale
Goodwill [Line Items]
Impairment of long-lived assets classified as held for sale						$ 8,000,000	5,000,000
Product/patent assets
Goodwill [Line Items]
Impairment of finite-lived intangible assets						$ 3,000,000	$ 60,000,000

INTANGIBLE ASSETS AND GOODWIL_4

INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2019	$ 444
2020	1,623
2021	1,374
2022	1,224
2023	1,080
2024	952
Thereafter	2,238
Net Carrying Amount	$ 8,935	$ 10,267

INTANGIBLE ASSETS AND GOODWIL_5

INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Millions	Oct. 01, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Change in the carrying amount of goodwill
Balance at the beginning of the period				$ 13,142	$ 15,593	$ 15,593
Impairments		$ 0	$ 0	0	(2,213)
Goodwill reclassified to assets held for sale				(18)		(2)
Acquisition of certain assets of Synergy				3
Foreign exchange and other				(75)		(127)
Balance at the end of the period		13,052		13,052		13,142
Ortho Dermatologics
Change in the carrying amount of goodwill
Impairments						(2,213)
Dentistry Reporting Unit
Change in the carrying amount of goodwill
Impairments	$ (109)					(109)
Bausch Lomb/ International
Change in the carrying amount of goodwill
Balance at the beginning of the period				5,805	6,016	6,016
Realignment of Global Solta reporting unit goodwill						(82)
Goodwill reclassified to assets held for sale				(18)		(2)
Foreign exchange and other				(75)		(127)
Balance at the end of the period		5,712		5,712		5,805
Branded Rx
Change in the carrying amount of goodwill
Balance at the beginning of the period					6,631	6,631
Realignment of Global Solta reporting unit goodwill						115
Realignment of segment goodwill						(4,533)
Branded Rx | Ortho Dermatologics
Change in the carrying amount of goodwill
Impairments						(2,213)
U.S. Diversified Products
Change in the carrying amount of goodwill
Balance at the beginning of the period					$ 2,946	2,946
Realignment of Global Solta reporting unit goodwill						(33)
Realignment of segment goodwill						(2,913)
Salix
Change in the carrying amount of goodwill
Balance at the beginning of the period				3,156
Realignment of segment goodwill						3,156
Acquisition of certain assets of Synergy				3
Balance at the end of the period		3,159		3,159		3,156
Ortho Dermatologics
Change in the carrying amount of goodwill
Balance at the beginning of the period				1,267
Realignment of segment goodwill						1,267
Balance at the end of the period		1,267		1,267		1,267
Diversified Products
Change in the carrying amount of goodwill
Balance at the beginning of the period				2,914
Realignment of segment goodwill						3,023
Balance at the end of the period		$ 2,914		$ 2,914		2,914
Diversified Products | Dentistry Reporting Unit
Change in the carrying amount of goodwill
Impairments						$ (109)

ACCRUED AND OTHER CURRENT LIA_3

ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Product rebates	$ 987	$ 998
Product returns	679	813
Interest	388	273
Employee compensation and benefit costs	291	301
Income taxes payable	150	167
Other	703	645
Accrued and other current liabilities	$ 3,198	$ 3,197

FINANCING ARRANGEMENTS - Summar

FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)	Sep. 30, 2019	May 23, 2019	Mar. 08, 2019	Dec. 31, 2018	Jun. 01, 2018	Mar. 26, 2018
Long-term debt, net of unamortized debt discount
Principal Amount	$ 23,841,000,000			$ 24,632,000,000
Total long-term debt and other	23,566,000,000			24,305,000,000
Less: Current portion of long-term debt and other	100,000,000			228,000,000
Non-current portion of long-term debt	23,466,000,000			24,077,000,000
Term Loan B Facility Due June 2025
Long-term debt, net of unamortized debt discount
Principal Amount	3,932,000,000			4,394,000,000
Total long-term debt and other	3,826,000,000			4,269,000,000
Term Loan B Facility Due November 2025
Long-term debt, net of unamortized debt discount
Principal Amount	$ 1,312,000,000			1,481,000,000
Stated interest rate on debt (as a percent)	4.79%
Total long-term debt and other	$ 1,293,000,000			1,456,000,000
Senior Secured Notes | 6.50% Senior Secured Notes Due March 2022
Long-term debt, net of unamortized debt discount
Principal Amount	$ 1,250,000,000			1,250,000,000
Stated interest rate on debt (as a percent)	6.50%
Total long-term debt and other	$ 1,241,000,000			1,239,000,000
Senior Secured Notes | 7.00% Senior Secured Notes Due March 2024
Long-term debt, net of unamortized debt discount
Principal Amount	$ 2,000,000,000			2,000,000,000
Stated interest rate on debt (as a percent)	7.00%
Total long-term debt and other	$ 1,982,000,000			1,979,000,000
Senior Secured Notes | 5.50% Senior Secured Notes Due November 2025
Long-term debt, net of unamortized debt discount
Principal Amount	$ 1,750,000,000			1,750,000,000
Stated interest rate on debt (as a percent)	5.50%
Total long-term debt and other	$ 1,732,000,000			1,730,000,000
Senior Secured Notes | 5.75% Senior Secured Notes Due August 2027
Long-term debt, net of unamortized debt discount
Principal Amount	$ 500,000,000			0
Stated interest rate on debt (as a percent)	5.75%
Total long-term debt and other	$ 493,000,000			0
Senior Unsecured Notes | 5.625% Senior Notes Due December 2021
Long-term debt, net of unamortized debt discount
Principal Amount	$ 0			700,000,000
Stated interest rate on debt (as a percent)	5.625%		5.625%
Total long-term debt and other	$ 0			697,000,000
Senior Unsecured Notes | 5.50% Senior Notes Due March 2023
Long-term debt, net of unamortized debt discount
Principal Amount	$ 402,000,000			1,000,000,000
Stated interest rate on debt (as a percent)	5.50%		5.50%
Total long-term debt and other	$ 400,000,000			995,000,000
Senior Unsecured Notes | 5.875% Senior Notes Due May 2023
Long-term debt, net of unamortized debt discount
Principal Amount	$ 1,548,000,000			3,250,000,000
Stated interest rate on debt (as a percent)	5.875%		5.875%
Total long-term debt and other	$ 1,540,000,000			3,229,000,000
Senior Unsecured Notes | 4.50% Senior Notes euro-denoted debt Due May 2023
Long-term debt, net of unamortized debt discount
Principal Amount	$ 1,635,000,000			1,720,000,000
Stated interest rate on debt (as a percent)	4.50%
Total long-term debt and other	$ 1,626,000,000			1,709,000,000
Senior Unsecured Notes | 6.125% Senior Notes Due April 2025
Long-term debt, net of unamortized debt discount
Principal Amount	$ 3,250,000,000			3,250,000,000
Stated interest rate on debt (as a percent)	6.125%
Total long-term debt and other	$ 3,229,000,000			3,226,000,000
Senior Unsecured Notes | 9.00% Senior Notes Due December 2025
Long-term debt, net of unamortized debt discount
Principal Amount	$ 1,500,000,000			1,500,000,000
Stated interest rate on debt (as a percent)	9.00%
Total long-term debt and other	$ 1,472,000,000			1,469,000,000
Senior Unsecured Notes | 9.25% Senior Notes Due April 2026
Long-term debt, net of unamortized debt discount
Principal Amount	$ 1,500,000,000			1,500,000,000
Stated interest rate on debt (as a percent)	9.25%					9.25%
Total long-term debt and other	$ 1,484,000,000			1,482,000,000
Senior Unsecured Notes | 8.50% Senior Notes Due January 2027
Long-term debt, net of unamortized debt discount
Principal Amount	$ 1,750,000,000			750,000,000
Stated interest rate on debt (as a percent)	8.50%				8.50%
Total long-term debt and other	$ 1,756,000,000			738,000,000
Senior Unsecured Notes | 7.00 % Senior Notes Due January 2028
Long-term debt, net of unamortized debt discount
Principal Amount	$ 750,000,000			0
Stated interest rate on debt (as a percent)	7.00%	7.00%
Total long-term debt and other	$ 740,000,000			0
Senior Unsecured Notes | 7.25 % Senior Notes Due May 2029
Long-term debt, net of unamortized debt discount
Principal Amount	$ 750,000,000			0
Stated interest rate on debt (as a percent)	7.25%	7.25%
Total long-term debt and other	$ 740,000,000			0
Senior Unsecured Notes | Other
Long-term debt, net of unamortized debt discount
Principal Amount	12,000,000			12,000,000
Total long-term debt and other	12,000,000			12,000,000
Revolving Credit Facility | Revolving Credit Facility Due June 2023
Long-term debt, net of unamortized debt discount
Principal Amount	$ 0			75,000,000
Stated interest rate on debt (as a percent)	5.04%
Total long-term debt and other	$ 0			$ 75,000,000

FINANCING ARRANGEMENTS - Covena

FINANCING ARRANGEMENTS - Covenant Compliance (Details)	Sep. 30, 2019
Revolving Credit Facility
Debt Instrument [Line Items]
Secured leverage ratio	4

FINANCING ARRANGEMENTS - Senior

FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)

May 23, 2019

Mar. 08, 2019

Dec. 27, 2018

Nov. 27, 2018

Jun. 01, 2018

Mar. 26, 2018

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Oct. 31, 2019

Dec. 31, 2018

Jan. 01, 2018

Debt Instrument [Line Items]

Repayments of long-term debt

$ 3,956,000,000

$ 8,200,000,000

Net proceeds from the issuance of debt

3,238,000,000

7,471,000,000

Loss on extinguishment of debt

$ 8,000,000

$ 0

$ 0

40,000,000

$ 75,000,000

Debt issuance costs

$ 25,000,000

$ 74,000,000

Debt modification costs

4,000,000

Long-term debt

$ 23,566,000,000

$ 23,566,000,000

$ 24,305,000,000

Series F Tranche B Term Loan Facility

Debt Instrument [Line Items]

Repayments of long-term debt

3,315,000,000

Stated interest rate on debt (as a percent)

5.04%

5.04%

Loss on extinguishment of debt

$ 48,000,000

Revolving Credit Facility Due June 2023 | Eurocurrency rate | Minimum

Debt Instrument [Line Items]

Variable rate (as a percentage)

0.00%

Revolving Credit Facility Due June 2023 | Canada Bankers Acceptance Rate

Debt Instrument [Line Items]

Variable rate (as a percentage)

1.00%

Revolving Credit Facility Due June 2023 | Canada Bankers Acceptance Rate | Minimum

Debt Instrument [Line Items]

Variable rate (as a percentage)

0.00%

Term Loan B Facility Due June 2025

Debt Instrument [Line Items]

Debt term

7 years

7 years

Principal amount

$ 1,500,000,000

$ 4,565,000,000

Long-term debt

$ 3,826,000,000

$ 3,826,000,000

4,269,000,000

Annual amortization rate (as a percent)

5.00%

5.00%

Term Loan B Facility Due June 2025 | Eurocurrency rate

Debt Instrument [Line Items]

Variable rate (as a percentage)

3.00%

Term Loan B Facility Due June 2025 | Base Rate

Debt Instrument [Line Items]

Variable rate (as a percentage)

2.00%

Senior Secured Credit Facilities

Debt Instrument [Line Items]

Debt covenant, mandatory prepayments, percentage net cash proceeds, property and asset losses

100.00%

Debt covenant, mandatory prepayments, percentage net cash proceeds, incurrence of debt

100.00%

Debt covenant, mandatory prepayments, percentage of consolidated excess cash flow

50.00%

Debt covenant, mandatory prepayments, percentage net cash proceeds, asset sales

100.00%

Senior Secured Credit Facilities | Federal Funds

Debt Instrument [Line Items]

Variable rate (as a percentage)

0.50%

Senior Secured Credit Facilities | Eurocurrency rate

Debt Instrument [Line Items]

Variable rate (as a percentage)

1.00%

Senior Secured Credit Facilities | Eurocurrency rate | Minimum

Debt Instrument [Line Items]

Variable rate (as a percentage)

0.00%

Term Loan B Facility Due November 2025

Debt Instrument [Line Items]

Stated interest rate on debt (as a percent)

4.79%

4.79%

Long-term debt

$ 1,293,000,000

$ 1,293,000,000

1,456,000,000

Annual amortization rate (as a percent)

5.00%

5.00%

Term Loan B Facility Due November 2025 | Eurocurrency rate

Debt Instrument [Line Items]

Variable rate (as a percentage)

2.75%

Term Loan B Facility Due November 2025 | Base Rate or Prime Rate

Debt Instrument [Line Items]

Variable rate (as a percentage)

1.75%

Senior Unsecured Notes

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 32,000,000

$ 26,000,000

Senior Unsecured Notes | 5.375% Senior Notes Due March 2020

Debt Instrument [Line Items]

Repayments of long-term debt

$ 691,000,000

Stated interest rate on debt (as a percent)

5.375%

Senior Unsecured Notes | 6.75% Senior Notes Due August 2021

Debt Instrument [Line Items]

Repayments of long-term debt

$ 578,000,000

Stated interest rate on debt (as a percent)

6.75%

Senior Unsecured Notes | 7.25% Senior Notes Due July 2022

Debt Instrument [Line Items]

Repayments of long-term debt

$ 550,000,000

Stated interest rate on debt (as a percent)

7.25%

Senior Unsecured Notes | 6.375% Senior Notes Due October 2020

Debt Instrument [Line Items]

Repayments of long-term debt

$ 146,000,000

Stated interest rate on debt (as a percent)

6.375%

6.375%

Senior Unsecured Notes | 8.50% Senior Notes Due January 2027

Debt Instrument [Line Items]

Principal amount

$ 1,000,000,000

Stated interest rate on debt (as a percent)

8.50%

8.50%

8.50%

Net proceeds from the issuance of debt

$ 750,000,000

Long-term debt

$ 1,756,000,000

$ 1,756,000,000

738,000,000

Senior Unsecured Notes | 7.50% Senior Notes Due July 2021

Debt Instrument [Line Items]

Repayments of long-term debt

$ 17,000,000

$ 1,483,000,000

Stated interest rate on debt (as a percent)

7.50%

Loss on extinguishment of debt

$ 43,000,000

Revolving Credit Facility

Debt Instrument [Line Items]

Maximum borrowing capacity

$ 1,500,000,000

Quarterly amortization payments

1,226,000,000

Threshold for incremental borrowings

$ 1,000,000,000

$ 1,000,000,000

Threshold for incremental borrowings, percentage of adjusted EBITDA

28.50%

28.50%

Secured leverage ratio

4

4

Revolving Credit Facility | Revolving Credit Facility Due June 2023

Debt Instrument [Line Items]

Maximum borrowing capacity

$ 1,225,000,000

Alternate debt term, number of days prior to scheduled maturity of principal amount in excess of threshold

91 days

Alternate debt term, principal amount in excess of threshold

$ 1,000,000,000

Stated interest rate on debt (as a percent)

5.04%

5.04%

Long-term debt

$ 0

$ 0

$ 75,000,000

Remaining borrowings

$ 1,055,000,000

$ 1,055,000,000

Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Minimum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.25%

Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Maximum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.50%

Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Eurocurrency rate | Minimum

Debt Instrument [Line Items]

Variable rate (as a percentage)

2.50%

Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Eurocurrency rate | Maximum

Debt Instrument [Line Items]

Variable rate (as a percentage)

3.00%

Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Base Rate | Minimum

Debt Instrument [Line Items]

Variable rate (as a percentage)

1.50%

Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Base Rate | Maximum

Debt Instrument [Line Items]

Variable rate (as a percentage)

2.00%

Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Subsequent Event

Debt Instrument [Line Items]

Net borrowings

$ 200,000,000

Revolving Credit Facility | Senior Secured Notes

Debt Instrument [Line Items]

Secured leverage ratio

3.50

3.50

Letter of Credit | Revolving Credit Facility Due June 2023

Debt Instrument [Line Items]

Long-term debt

$ 170,000,000

$ 170,000,000

FINANCING ARRANGEMENTS - Seni_2

FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)	May 23, 2019	Mar. 08, 2019	Mar. 26, 2018	Apr. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 01, 2018
Debt Instrument [Line Items]
Redemption price percentage to change in control (as a percent)							101.00%
Repayments of long-term debt							$ 3,956,000,000	$ 8,200,000,000
Loss on extinguishment of debt		$ 8,000,000			$ 0	$ 0	$ 40,000,000	$ 75,000,000
Senior Unsecured Notes
Debt Instrument [Line Items]
Redemption price percentage to change in control (as a percent)										101.00%
Loss on extinguishment of debt	$ 32,000,000		$ 26,000,000
5.75% Senior Secured Notes Due August 2027 | Senior Secured Notes
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)		5.75%
Principal amount		$ 500,000,000
Redemption price percentage (as a percent)									100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings									40.00%
8.50% Senior Notes Due January 2027 | Senior Unsecured Notes
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)					8.50%		8.50%				8.50%
Principal amount		$ 1,000,000,000
5.875% Senior Notes Due May 2023 | Senior Unsecured Notes
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)		5.875%			5.875%		5.875%
Repayments of long-term debt		$ 584,000,000
5.625% Senior Notes Due December 2021 | Senior Unsecured Notes
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)		5.625%			5.625%		5.625%
Repayments of long-term debt		$ 518,000,000		$ 182,000,000
5.50% Senior Notes Due March 2023 | Senior Unsecured Notes
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)		5.50%			5.50%		5.50%
Repayments of long-term debt		$ 216,000,000
Senior Secured Notes and Senior Unsecured Notes
Debt Instrument [Line Items]
Principal amount				$ 1,500,000,000

FINANCING ARRANGEMENTS - Seni_3

FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details) - USD ($)	May 23, 2019	Mar. 08, 2019	Jun. 01, 2018	Mar. 26, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2018
Debt Instrument [Line Items]
Redemption price percentage to change in control (as a percent)							101.00%
Loss on extinguishment of debt		$ 8,000,000			$ 0	$ 0	$ 40,000,000	$ 75,000,000
Net proceeds from the issuances of long-term debt							$ 3,238,000,000	$ 7,471,000,000
Weighted average effective interest rate (as a percent)					6.39%		6.39%			6.23%
Unsecured Debt
Debt Instrument [Line Items]
Redemption price percentage to change in control (as a percent)									101.00%
Repurchased principal amount				$ 1,500,000,000
Loss on extinguishment of debt	$ 32,000,000			$ 26,000,000
Unsecured Debt | 9.25% Senior Notes Due April 2026
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)				9.25%	9.25%		9.25%
Proceeds from debt issuance				$ 1,500,000,000
Unsecured Debt | 5.375% Senior Notes Due March 2020
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)			5.375%
Repurchased principal amount				$ 1,017,000,000
Unsecured Debt | 6.375% Senior Notes Due October 2020
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)			6.375%	6.375%
Repurchased principal amount				$ 411,000,000
Unsecured Debt | 6.75% Senior Notes Due August 2021
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)			6.75%
Repurchased principal amount				$ 72,000,000
Unsecured Debt | 8.50% Senior Notes Due January 2027
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)			8.50%		8.50%		8.50%
Net proceeds from the issuances of long-term debt			$ 750,000,000
Principal amount		$ 1,000,000,000
Unsecured Debt | 7.00 % Senior Notes Due January 2028
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)	7.00%				7.00%		7.00%
Proceeds from debt issuance	$ 750,000,000
Redemption price percentage (as a percent)	100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings	40.00%
Unsecured Debt | 7.25 % Senior Notes Due May 2029
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)	7.25%				7.25%		7.25%
Proceeds from debt issuance	$ 750,000,000
Redemption price percentage (as a percent)	100.00%
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings	40.00%
Unsecured Debt | 5.875% Senior Notes Due May 2023
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)		5.875%			5.875%		5.875%
Repurchased principal amount	$ 1,118,000,000
Unsecured Debt | 5.50% Senior Notes Due March 2023
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)		5.50%			5.50%		5.50%
Repurchased principal amount	$ 382,000,000

FINANCING ARRANGEMENTS - Aggreg

FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Remainder of 2019	$ 100
2020	0
2021	203
2022	1,553
2023	3,788
2024	2,303
Thereafter	15,894
Total debt obligations	23,841	$ 24,632
Unamortized premiums, discounts and issuance costs	(275)
Total long-term debt and other	$ 23,566	$ 24,305

FINANCING ARRANGEMENTS - Maturi

FINANCING ARRANGEMENTS - Maturities and Mandatory Payments (Details) - USD ($) $ in Millions	Oct. 31, 2019	Sep. 30, 2019	May 23, 2019	Mar. 08, 2019	Mar. 26, 2018
Revolving Credit Facility Due June 2023 | Revolving Credit Facility
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)		5.04%
Unsecured Debt
Debt Instrument [Line Items]
Repurchased principal amount					$ 1,500
Unsecured Debt | 5.875% Senior Notes Due May 2023
Debt Instrument [Line Items]
Repurchased principal amount			$ 1,118
Stated interest rate on debt (as a percent)		5.875%		5.875%
Subsequent Event
Debt Instrument [Line Items]
Repurchased principal amount	$ 100
Subsequent Event | Revolving Credit Facility Due June 2023 | Revolving Credit Facility
Debt Instrument [Line Items]
Net borrowings	$ 200
Subsequent Event | Unsecured Debt | 5.875% Senior Notes Due May 2023
Debt Instrument [Line Items]
Stated interest rate on debt (as a percent)	5.875%

PENSION AND POSTRETIREMENT EM_3

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Pension Benefit Plans | U.S. Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 1	$ 1
Interest cost	6	5
Expected return on plan assets	(10)	(11)
Amortization of prior service credit	0	0
Amortization of net loss	0	0
Net periodic (benefit) cost	(3)	(5)
Pension Benefit Plans | Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	2	2
Interest cost	4	4
Expected return on plan assets	(4)	(4)
Amortization of prior service credit	(1)	(1)
Amortization of net loss	1	1
Net periodic (benefit) cost	2	2
Postretirement Benefit Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0
Interest cost	1	1
Expected return on plan assets	0	0
Amortization of prior service credit	(2)	(2)
Amortization of net loss	0	0
Net periodic (benefit) cost	$ (1)	$ (1)

LEASES - Narrative (Details)

LEASES - Narrative (Details) - USD ($) $ in Millions	Jan. 01, 2019	Sep. 30, 2019
Lessee, Lease, Description [Line Items]
Finance lease		$ 0
Sub-lease income		0
Right-of-use assets obtained in exchange for new operating lease liabilities, excluding amount recognized upon adoption of new accounting standard		$ 28
Right-of-use assets obtained in exchange for new operating lease liabilities, upon adoption of new accounting standard	$ 282
Minimum
Lessee, Lease, Description [Line Items]
Lease term		1 year
Lease renewal term		1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease term		20 years
Lease renewal term		5 years

LEASES - Right-of-use Assets an

LEASES - Right-of-use Assets and Right-of-use Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2019	Jan. 01, 2019
Right-of-use assets included in:
Other non-current assets	$ 263	$ 302
Lease liabilities included in:
Accrued and other current liabilities	49
Other non-current liabilities	235
Total lease liabilities	$ 284	$ 302

LEASES - Lease Expenses (Detail

LEASES - Lease Expenses (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating lease costs	$ 15	$ 47
Variable operating lease costs	3	12
Short-term lease expense	$ 1	$ 2

LEASES - Lease Additional Infor

LEASES - Lease Additional Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Leases [Abstract]
Cash paid from operating cash flows for amounts included in the measurement of lease liabilities	$ 56
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 28
Weighted-average remaining lease term	8 years 6 months
Weighted-average discount rate	6.20%

LEASES - Lease Future Payments,

LEASES - Lease Future Payments, Topic 842 (Details) - USD ($) $ in Millions	Sep. 30, 2019	Jan. 01, 2019
Leases [Abstract]
Remainder of 2019	$ 16
2020	63
2021	49
2022	39
2023	34
2024	28
Thereafter	146
Total	375
Less: Imputed interest	91
Total lease liabilities	284	$ 302
Less: Current portion	49
Non-current portion	$ 235

LEASES - Lease Future Payment_2

LEASES - Lease Future Payments, Topic 840 (Details) $ in Millions	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 78
2020	60
2021	44
2022	39
2023	32
Thereafter	166
Total	$ 419

SHARE-BASED COMPENSATION - Narr

SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)	Apr. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	May 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining unrecognized compensation expense related to non-vested awards			$ 119,000,000
Weighted average service period over which compensation cost is expected to be recognized (in years)			1 year 8 months 15 days
Chief Executive Officer | Performance-based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of long term incentives		$ 10,000,000
Number of shares canceled (in shares)		933,000
2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares authorized (in shares)				18,000,000
Common shares available for issuance (in shares)				20,000,000
Number of additional shares available for issuance (in shares)	11,900,000
Number of shares available for future grant (in shares)			9,916,000
2014 Plan | Non-employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate fair market value on awards granted during any calendar year	$ 750,000

SHARE-BASED COMPENSATION - Summ

SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Components and classification of share-based compensation expense
Share-based compensation expense	$ 26	$ 22	$ 77	$ 65
Research and development expenses
Components and classification of share-based compensation expense
Share-based compensation expense	2	3	7	7
Selling, general and administrative expenses
Components and classification of share-based compensation expense
Share-based compensation expense	24	19	70	58
Stock options
Components and classification of share-based compensation expense
Share-based compensation expense	5	6	17	17
RSUs
Components and classification of share-based compensation expense
Share-based compensation expense	$ 21	$ 16	$ 60	$ 48

SHARE-BASED COMPENSATION - Su_2

SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details) - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Stock options
Stock options
Granted (in shares)	1,725	2,106
Weighted average exercise price (in usd per share)	$ 23.16	$ 15.46
Weighted average grant date fair value of stock options (in usd per share)	$ 8.46	$ 7.82
Time-based RSUs
RSUs
Granted (in shares)	2,895	2,844
Weighted-average grant date fair value (in usd per share)	$ 23.93	$ 17.36
TSR performance-based RSUs
RSUs
Granted (in shares)	454	469
Weighted-average grant date fair value (in usd per share)	$ 34.53	$ 29.35
ROTC performance-based RSUs
RSUs
Granted (in shares)	505	409
Weighted-average grant date fair value (in usd per share)	$ 25.03	$ 18.80

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of AOCI (Details) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income
Total equity	$ 2,560	$ 2,688	$ 2,815	$ 3,237	$ 3,558	$ 5,944
Foreign currency translation adjustments
Accumulated Other Comprehensive Income
Total equity	(2,129)		(2,111)
Pension and postretirement benefit plan adjustments, net of tax
Accumulated Other Comprehensive Income
Total equity	(27)		(26)
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income
Total equity	$ (2,156)	$ (2,061)	$ (2,137)	$ (2,053)	$ (2,068)	$ (1,896)

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Amount reclassified from accumulated other comprehensive loss into operating results	$ 0	$ 0

RESEARCH AND DEVELOPMENT - Summ

RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Research and Development [Abstract]
Product related research and development	$ 114	$ 98	$ 329	$ 265
Quality assurance	9	9	28	28
Research and development	$ 123	$ 107	$ 357	$ 293

OTHER EXPENSE (INCOME), NET - S

OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Other Income and Expenses [Abstract]
Net (gain) loss on sale of assets	$ (1)	$ 26	$ (10)	$ 26
Acquisition-related costs	0	0	8	1
Litigation and other matters	9	(40)	12	(30)
Other, net	2	(1)	5	0
Other expense, net	$ 10	$ (15)	$ 15	$ (3)

OTHER EXPENSE (INCOME), NET - N

OTHER EXPENSE (INCOME), NET - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
In Process Research and Development
Finite-Lived Intangible Assets [Line Items]
Other, net	$ 9

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income taxes provision (benefit)	$ (18)	$ 51	$ (101)	$ 74
Tax expense (benefit) for discrete items			(46)	203
Tax benefit, royalty payments by affiliate			32
Income tax benefit related to filing certain tax returns			13
Tax charges related to changes in uncertain tax positions			1
Income tax benefit on ordinary income			55	129
Income tax charge for internal restructuring transactions				255
Income tax benefit related to impairment of intangible assets				$ 57
Valuation allowance against deferred tax assets	3,126		3,126		$ 2,913
Unrecognized tax benefits including interest and penalties	622		622		654
Unrecognized tax benefits related to interest and penalties	48		48		$ 42
Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate	$ 316		$ 316

LOSS PER SHARE - Schedule of Lo

LOSS PER SHARE - Schedule of Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Net loss attributable to Bausch Health Companies Inc.	$ (49)	$ (350)	$ (272)	$ (3,804)
Basic and diluted weighted-average common shares outstanding (in shares)	352.4	351.5	351.9	351.1
Basic and diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)	$ (0.14)	$ (1)	$ (0.77)	$ (10.83)

LOSS PER SHARE - Narrative (Det

LOSS PER SHARE - Narrative (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock Compensation Plan
Anti-dilutive shares not included in the computation of diluted earnings per share
Diluted effect of stock options and RSUs (in shares)	4,453	4,238	4,589	3,323
Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units
Anti-dilutive shares not included in the computation of diluted earnings per share
Diluted effect of stock options and RSUs (in shares)	5,363	3,750	5,363	3,979

LEGAL PROCEEDINGS - Legal Proce

LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2016	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Current accrued loss contingencies		$ 20
Investigation by the State of Texas, State's Medicaid Program
Loss Contingencies [Line Items]
Damages sought	$ 20

LEGAL PROCEEDINGS - Securities

LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)	Dec. 07, 2017insurance_policy_period	Oct. 31, 2015case	Sep. 16, 2016action	Sep. 30, 2019groupplantiff	Dec. 31, 2018action	Dec. 31, 2015case	Sep. 13, 2019shareholder	Sep. 10, 2019shareholder	Feb. 15, 2019entity
New Jersey | Unfavorable Regulatory Action
Loss Contingencies [Line Items]
Number of suits filed | action			3
Canada
Loss Contingencies [Line Items]
Number of suits filed | case						6
Canada | Violation of Canadian Provincial Securities Legislation
Loss Contingencies [Line Items]
Number of suits filed but not yet served | action					2
Number of entities, exercised opt-out right, pursuing action | entity									1
US Securities Litigation | New Jersey
Loss Contingencies [Line Items]
Number of groups of investors filing action | group				33
Number of plaintiffs asserting claims under the Connecticut Uniform Securities Act | plantiff				1
US Securities Litigation | New Jersey | Unfavorable Regulatory Action
Loss Contingencies [Line Items]
Number of suits filed | case		4
Insurance Coverage Lawsuit
Loss Contingencies [Line Items]
Number of distinct insurance policy periods | insurance_policy_period	2
Derivative Lawsuits
Loss Contingencies [Line Items]
Number of alleged stockholders, filed lawsuits | shareholder							2	2

LEGAL PROCEEDINGS - Antitrust (

LEGAL PROCEEDINGS - Antitrust (Details)	3 Months Ended
	Oct. 31, 2019case	Dec. 31, 2018plantiff
Generic Pharmaceuticals Pricing Antitrust Litigation
Loss Contingencies [Line Items]
Number of plaintiffs, filed amended complaint | plantiff		3
Glumetza Antitrust Litigation | Subsequent Event
Loss Contingencies [Line Items]
Number of putative antitrust class actions filed | case	6

LEGAL PROCEEDINGS - Intellectua

LEGAL PROCEEDINGS - Intellectual Property (Details)	1 Months Ended
	Sep. 30, 2019
Sandoz Litigation
Loss Contingencies [Line Items]
Stay of approval, period	30 months

LEGAL PROCEEDINGS - Product Lia

LEGAL PROCEEDINGS - Product Liability (Details) - case	Mar. 24, 2017	Jan. 31, 2019	Sep. 30, 2019	Dec. 31, 2015	Dec. 30, 2016
CANADA
Loss Contingencies [Line Items]
Number of suits filed				6
Shower to Shower Product Liability Litigation
Loss Contingencies [Line Items]
Number of lawsuits (165 lawsuits involving Shower to Shower body powder product)			165
Shower to Shower Product Liability Litigation | Pending Litigation
Loss Contingencies [Line Items]
Number of lawsuits (165 lawsuits involving Shower to Shower body powder product)			12
Shower to Shower Product Liability Litigation | CANADA
Loss Contingencies [Line Items]
Number of lawsuits (165 lawsuits involving Shower to Shower body powder product)			2
Shower to Shower Product Liability Litigation | BRITISH COLUMBIA
Loss Contingencies [Line Items]
Number of lawsuits (165 lawsuits involving Shower to Shower body powder product)			1
Shower to Shower Product Liability Litigation | QUEBEC
Loss Contingencies [Line Items]
Number of lawsuits (165 lawsuits involving Shower to Shower body powder product)			1
Johnson & Johnson Talcum Powder Litigation
Loss Contingencies [Line Items]
Number of lawsuits (165 lawsuits involving Shower to Shower body powder product)	1		6		3
Number of suits filed	2
Number of cases voluntarily dismissed			4
Johnson & Johnson Talcum Powder Litigation | DELAWARE
Loss Contingencies [Line Items]
Number of cases voluntarily dismissed		122
Number of cases voluntarily dismissed, refiling period			60 days
Number of cases voluntarily dismissed, refiled			0
Johnson & Johnson Talcum Powder Litigation | NEW JERSEY
Loss Contingencies [Line Items]
Number of lawsuits (165 lawsuits involving Shower to Shower body powder product)			4
Johnson & Johnson Talcum Powder Litigation, New Jersey
Loss Contingencies [Line Items]
Number of lawsuits (165 lawsuits involving Shower to Shower body powder product)			2
Number of cases not voluntarily dismissed			3
Johnson & Johnson Talcum Powder Litigation, Delaware
Loss Contingencies [Line Items]
Number of lawsuits (165 lawsuits involving Shower to Shower body powder product)			1

LEGAL PROCEEDINGS - General Civ

LEGAL PROCEEDINGS - General Civil Actions (Details) - USD ($) $ in Millions	Jan. 28, 2019	Apr. 30, 2018
Doctors Allergy Formula, LLC Litigation
Loss Contingencies [Line Items]
Damages sought		$ 23
Litigation with Former Salix CEO
Loss Contingencies [Line Items]
Damages sought	$ 30

LEGAL PROCEEDINGS - Completed o

LEGAL PROCEEDINGS - Completed or Inactive Matters (Details) - Settled Litigation $ in Millions	Aug. 19, 2019USD ($)	Sep. 30, 2019USD ($)	Mar. 31, 2015manufacturer
Contact Lens Antitrust Class Actions
Loss Contingencies [Line Items]
Number of manufacturers | manufacturer			3
Settlement, agreed to pay	$ 10
Mississippi Attorney General Consumer Protection Action
Loss Contingencies [Line Items]
Settlement, agreed to pay		$ 0

SEGMENT INFORMATION - Segment R

SEGMENT INFORMATION - Segment Revenues and Profit (Details) - USD ($) $ in Millions	Mar. 08, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Segment reporting information
Revenues		$ 2,209	$ 2,136	$ 6,377	$ 6,259
Amortization of intangible assets		(475)	(658)	(1,452)	(2,142)
Goodwill impairments		0	0	0	(2,213)
Asset impairments		(33)	(89)	(49)	(434)
Restructuring and integration costs		(4)	(3)	(28)	(16)
Acquisition-related contingent consideration		(3)	19	(2)	23
Other income (expense), net		(10)	15	(15)	3
Operating income (loss)		329	117	873	(2,409)
Interest income		2	3	9	9
Interest expense		(406)	(420)	(1,221)	(1,271)
Loss on extinguishment of debt	$ (8)	0	0	(40)	(75)
Foreign exchange and other		9	0	12	18
Loss before benefit from (provision for) income taxes		(66)	(300)	(367)	(3,728)
Bausch Lomb/International
Segment reporting information
Revenues		1,175	1,147	3,501	3,459
Salix
Segment reporting information
Revenues		551	460	1,505	1,323
Ortho Dermatologics
Segment reporting information
Revenues		147	176	407	457
Diversified Products
Segment reporting information
Revenues		336	353	964	1,020
Operating Segment
Segment reporting information
Revenues		2,209	2,136	6,377	6,259
Operating income (loss)		1,012	1,000	2,854	2,812
Operating Segment | Bausch Lomb/International
Segment reporting information
Revenues		1,175	1,147	3,501	3,459
Operating income (loss)		333	341	989	988
Operating Segment | Salix
Segment reporting information
Revenues		551	460	1,505	1,323
Operating income (loss)		375	304	995	868
Operating Segment | Ortho Dermatologics
Segment reporting information
Revenues		147	176	407	457
Operating income (loss)		58	88	156	190
Operating Segment | Diversified Products
Segment reporting information
Revenues		336	353	964	1,020
Operating income (loss)		246	267	714	766
Corporate
Segment reporting information
Operating income (loss)		$ (158)	$ (167)	$ (435)	$ (442)

SEGMENT INFORMATION - Disaggreg

SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
Revenues	$ 2,209	$ 2,136	$ 6,377	$ 6,259
Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	1,072	1,055	3,057	3,050
Devices
Disaggregation of Revenue [Line Items]
Revenues	421	394	1,257	1,207
OTC
Disaggregation of Revenue [Line Items]
Revenues	371	352	1,063	1,046
Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	316	307	914	870
Other revenues
Disaggregation of Revenue [Line Items]
Revenues	29	28	86	86
Bausch Lomb/ International
Disaggregation of Revenue [Line Items]
Revenues	1,175	1,147	3,501	3,459
Bausch Lomb/ International | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	217	222	670	667
Bausch Lomb/ International | Devices
Disaggregation of Revenue [Line Items]
Revenues	375	365	1,127	1,117
Bausch Lomb/ International | OTC
Disaggregation of Revenue [Line Items]
Revenues	371	352	1,063	1,046
Bausch Lomb/ International | Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	197	192	582	576
Bausch Lomb/ International | Other revenues
Disaggregation of Revenue [Line Items]
Revenues	15	16	59	53
Salix
Disaggregation of Revenue [Line Items]
Revenues	551	460	1,505	1,323
Salix | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	551	460	1,505	1,323
Salix | Devices
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Salix | OTC
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Salix | Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Salix | Other revenues
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Ortho Dermatologics
Disaggregation of Revenue [Line Items]
Revenues	147	176	407	457
Ortho Dermatologics | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	97	140	265	346
Ortho Dermatologics | Devices
Disaggregation of Revenue [Line Items]
Revenues	46	29	130	90
Ortho Dermatologics | OTC
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Ortho Dermatologics | Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Ortho Dermatologics | Other revenues
Disaggregation of Revenue [Line Items]
Revenues	4	7	12	21
Diversified Products
Disaggregation of Revenue [Line Items]
Revenues	336	353	964	1,020
Diversified Products | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	207	233	617	714
Diversified Products | Devices
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Diversified Products | OTC
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Diversified Products | Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	119	115	332	294
Diversified Products | Other revenues
Disaggregation of Revenue [Line Items]
Revenues	$ 10	$ 5	$ 15	$ 12

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details) - product	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
Number of products represented of total revenue	10	10
Product Concentration Risk | Revenues
Disaggregation of Revenue [Line Items]
Concentration risk percentage	38.00%	36.00%

SEGMENT INFORMATION - Revenue b

SEGMENT INFORMATION - Revenue by Geographic Area (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 2,209	$ 2,136	$ 6,377	$ 6,259
U.S. and Puerto Rico
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1,369	1,329	3,851	3,766
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	86	91	276	273
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	85	78	252	231
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	67	59	181	165
Mexico
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	56	56	158	153
Egypt
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	55	45	157	134
France
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	45	46	156	159
Poland
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	49	49	156	164
Russia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	47	38	124	106
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	33	38	119	130
United Kingdom
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	27	29	85	87
Italy
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	18	19	62	64
Spain
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	18	17	62	61
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 254	$ 242	$ 738	$ 766

SEGMENT INFORMATION - Major Cus

SEGMENT INFORMATION - Major Customers (Details) - Revenues - Customer Concentration	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
McKesson Corporation (including McKesson Specialty)
Revenue, Major Customer [Line Items]
Concentration risk percentage	17.00%	18.00%
AmerisourceBergen Corporation
Revenue, Major Customer [Line Items]
Concentration risk percentage	17.00%	18.00%
Cardinal Health, Inc.
Revenue, Major Customer [Line Items]
Concentration risk percentage	14.00%	13.00%

Uncategorized Items - bauschhea

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,209,000,000
Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	1,209,000,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,209,000,000